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SUMMARY 
 
This thesis mainly deals with some biochemical aspects regarding the efficacy of 
novel platinum anticancer compounds alone and in combination with mangiferin, as 
part of a broader study in which both chemistry and biochemistry are involved.  
Various novel diamine and N-S donor chelate compounds of platinum II and IV have 
been developed in which factors such as stereochemistry, ligand exchange rate and 
biocompatibility were considered as additional parameters.  In the first order testing, 
each of these compounds was tested with reference to their “killing” potential by 
comparing their rate of killing, over a period of 48 hours with those of cisplatin and 
oxaliplatin.  Numerous novel compounds were tested in this way, using the MTT cell 
viability assay and the three cancer cell lines MCF7, HT29 and HeLa.  Although only 
a few could be regarded as equal to or even better than cisplatin, CPA7 and 
oxaliplatin, the testing of these compounds on cancer cells provided useful knowledge 
for the further development of novel compounds. 
 
Three of the better compounds, namely Yol 25, Yol 29.1 and Mar 4.1.4 were selected 
for further studies, together with oxaliplatin and CPA7 as positive controls, to obtain 
more detailed knowledge of their anticancer action, both alone and when applied in 
combination with mangiferin.  In addition to the above, resistant cells were produced 
for each of the three different cell lines tested and all the selected compounds, both in 
the presence and absence of mangiferin.  The effects of these treatments on the 
activation of NFĸB when applied to normal and resistant cell lines were also 
investigated.   
 
All the compounds induced apoptosis in the cell lines tested as well as alter the DNA 
cycle at one or more phase.  Additionally, combination of these compounds with 
mangiferin enhanced the above-mentioned effects.  Mangiferin decreases the IC50 
values of the platinum drugs by up to 3.4 times and, although mangiferin alone did not 
induce cell cycle arrest, the presence of mangiferin in combination with oxaliplatin 
and Yol 25 shows an earlier and greatly enhanced delay in the S-phase, while cells 
treated with CPA7, Yol 29.1 and Mar 4.1.4 in combination with mangiferin showed a 
later, but greatly enhanced delay in the S-phase.  It was also found that mangiferin 
acts as an NFĸB inhibitor when applied in combination with these drugs, which, in 
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turn, reduces the occurrence of resistance in the cell lines.  Resistance to oxaliplatin 
was counteracted by the combination with mangiferin in HeLa and HT29, but not in 
MCF7 cells, while resistance to CPA7 was only counteracted in the MCF7 cell line.  
Yol 25 and Mar 4.1.4 did not seem to induce resistance in HeLa and MCF7 cells, but 
did in HT29 cells, whereas Yol 29.1 caused resistance in HeLa and HT29 cells, but 
not in MCF7 cells.   
 
Finally, an effort was made to evaluate the different compounds by comparing them 
with respect to their properties relating to anticancer action with and without the 
addition of mangiferin. 
 
 
Keywords:  apoptosis, platinum anticancer compounds, mangiferin, resistance, 
NFκB, cancer cell lines.
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CHAPTER 1 
LITERATURE REVIEW 
 
1.1 INTRODUCTION 
 
Cancer is an important public health concern around the world and is a significant 
cause of death in the human population (Parker et al. 1997 and Walker and Walker, 
1999).  The application of inorganic chemistry to medicine (“Elemental Medicine”) is 
a fast developing field, and novel therapeutic and diagnostic metal complexes are now 
having an impact on medical practice.  Advances in bio-inorganic chemistry are vital 
for improving the design of compounds to lessen toxic side effects and understand 
their mechanisms of action (Sadler and Guo, 1998). 
 
The platinum drugs represent a unique and important class of anti-tumour agents.  The 
discovery of the neutral, square planar, coordination complex cis-
diamminedichloroplatinum(II) (cisplatin) in the 1970’s has revolutionized the 
chemotherapy of human cancer (Gonzalez et al. 2001).  Cisplatin begins its 
interaction with cancer DNA by binding to the nitrogen atoms of the DNA bases, 
typically guanine.  Hence, these cisplatin adducts aid in destabilization of the DNA.  
Cisplatin binding severely distorts DNA by twisting, unwinding, and shortening the 
duplex.  It causes significant bending of about 40° away from the site of attachment.  
Although the overall structure of the double helix remains intact, the distortion is 
absorbed by conformational changes in the sugar-phosphate backbone near the 
platinum lesion.  This propagates steric constraints that lead to a loss in helix stability 
(Siddik, 2003, Scheeff et al. 1999).  
  
When cisplatin was used in combination chemotherapy with other drugs, it achieved 
cure rates of up to 90% against testicular cancer, and also displayed significant 
activity against other types of tumours (Gupta et al. 2004).  The results of 
radiotherapy alone are unsatisfactory, since overall only 5-7% of the patients survive 
more than 5 years and Winterhalder et al. (2004) showed that there is a definite 
survival benefit of adding platinum based chemotherapy to radiation for the treatment 
of non-small-cell lung cancer. 
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Unfortunately the full therapeutic potential of cisplatin has not been realized due to 
the serious side effects and emergence of cisplatin-resistant tumour cells related to 
treatment with cisplatin.  Extensive hydration, improved schedules of administration, 
alternate routes of administration and use of protective agents against specific side 
effects are some of the protective methods employed that have allowed the use of 
higher doses of cisplatin against cisplatin-resistant tumours and has extended the list 
of tumour systems responsive to cisplatin chemotherapy (Walker and Walker, 1999).   
 
The incorporation of cisplatin into a number of cisplatin-based anti-cancer drug 
combinations has improved its efficiency and allowed the use of lower doses of 
cisplatin, which reduces its toxic side effects.  The availability of cisplatin analogues 
with reduced toxicity, but increased efficiency against cisplatin-resistant tumours, has 
expanded the potential scope and therapeutic promise of the platinum anti-cancer 
agents.  Cisplatin is widely used for the treatment of many malignancies, including 
testicular, ovarian, bladder, cervical, head and neck, and small-cell and non-small-cell 
lung cancers and the development of chemotherapy with the platinum anti-tumour 
compounds is still in progress. (Gonzalez et al. 2001 and Walker and Walker, 1999). 
 
At the same time traditional medicine is an integral part of South African cultural life, 
a position that is unlikely to change to any significant degree in years to come.  It is 
estimated that between 12 and 15 million South Africans depend on traditional herbal 
medicines from as many as 700 indigenous plant species (Duncan et al. 1999). 
 
The anticancer properties of tea are well known, and the tumour inhibition potential of 
certain polyphenolic compounds from green and black teas has been well documented 
(Marnewick et al. 2000 and Marnewick et al. 2004).  Honeybush tea (Cyclopia 
intermedia) is a South African herbal beverage that is currently receiving prominent 
attention.  Honeybush tea is prepared from the leaves, stems and flowers of several 
Cyclopia spp.  The major phenolic components of the unprocessed South African 
honeybush tea are the xanthone, mangiferin and the flavanone, hesperidin 
(Marnewick et al. 2005). 
 
In a study at the University of Dundee (Scotland) it has been found that the 
development of anti-cancer drugs that can “switch” the function of NF-κB (nuclear 
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factor ĸ B) from anti-apoptotic to pro-apoptotic may prove to be beneficial in the fight 
against cancer.  Supranormal activation of NF-κB is connected to cancer.  Active NF-
κB promotes tumour growth by increasing the transcription of genes that are:  anti-
apoptotic; inducers of cell proliferation; pro-angiogenic; pro-metastatic and 
responsible for other cellular mechanisms related to tumour growth.  Hence, tumour 
prevention may be achieved through inhibition of abnormally active NF-κB (Perkins, 
2000 and Perkins, 2004). 
 
Mangiferin is a natural polyphenol known to exhibit anti-inflammatory, antioxidant, 
and antiviral effects, though the molecular mechanism underlying these effects has 
not been well characterized.  NF-κB plays an important role in these processes; hence 
it may be possible that mangiferin modulates NF-κB activation.  Sarkar et al. (2004) 
showed that mangiferin blocks tumour necrosis factor (TNF)-induced NF-κB 
activation and NF-κB-dependent genes like ICAM1 and COX2.  The effect was 
mediated through inhibition of IĸB (inhibitor proteins) -kinase complex (IKK) 
activation and subsequent blocking of phosphorylation and degradation of IκB-α 
(inhibitor protein α).  In addition, mangiferin inhibits TNF-induced p65 
phosphorylation as well as translocation to the nucleus and also inhibits NF-κB 
activation induced by other inflammatory agents.   
 
Mangiferin, similar to other known antioxidants, inhibits TNF-induced reactive 
oxygen intermediate (ROI) generation.  It enhances glutathione (GSH) levels by 
almost 2-fold more than other antioxidants, and at the same time it decreases the 
levels of oxidized glutathione (GSSG) and increases the activity of catalase.  
Depletion of GSH by buthionine sulfoximine led to a significant reversal of 
mangiferin effect.  Hence, mangiferin, with its ability to inhibit NF-κB and increase 
the intracellular GSH levels, may prove to be a potent drug for anti-inflammatory and 
antioxidant therapy.  Mangiferin-mediated down-regulation of NF-κB also shows 
potential for chemotherapeutic agent-mediated cell death, suggesting a role in 
combination therapy for cancer (Sarkar et al. 2004).  However, it is known that high 
GSH levels inhibits the anticancer action of platinum drugs (via detoxification) as 
well as plays a role in the induction of resistance towards these compounds in cancer 
cells (Turchi, 2006).  Therefore it will be necessary to investigate the combined 
effects of mangiferin and platinum anticancer drugs, as an increased intake of 
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mangiferin may not necessarily lead to increased action in the chemotherapeutic 
action of platinum drugs.   
 
A programme for the development of novel platinum containing anticancer agents has 
been initiated at this university.  The expertise of both the chemistry and biochemistry 
departments has been coupled in a joint effort to cover both the chemical and 
biochemical aspects of the development of such novel compounds.  The Research 
Unit for Platinum Group Chemistry, plan, synthesize and characterise the chemical 
aspects and the Department of Biochemistry and Microbiology evaluates the 
anticancer action in terms of their efficacy in killing a number of types of cancer cells 
as well as their mode of anticancer action.  The latter study is essential to provide 
feedback, which enables a correlation of their anticancer properties with their 
structure and physical chemical characteristics.  
 
The combined anticancer effect of platinum drugs and mangiferin, which have 
different modes of action, might prove to be very useful in the treatment of cancer.  
Sarkar et al. (2004) has also shown that when cells were pre-treated with mangiferin 
for 3 hours prior to exposure to cisplatin, an enhancement of approximately 20% in 
the anticancer action of cisplatin could be observed.  Therefore the combined mode of 
action of these two treatments needs to be investigated further. 
 
Cancer is a universal problem, which affects many people.  Cisplatin showed great 
promise in the treatment of cancer, however, due to the numerous toxic side effects 
and the emergence of cisplatin resistant cell lines, drugs with less toxic side effects, 
improved cytotoxicity against cancer cells and activity against cisplatin resistant cell 
lines are urgently needed.  If mangiferin, a natural polyphenol found in Cyclopia spp., 
aids in the enhanced anticancer action of some novel platinum containing complexes, 
a new combination therapy against cancer can be proposed.  Furthermore, the use of 
traditional herbal medicines in these treatments might render it more acceptable to 
many South Africans.  Hence, the development and screening of novel anti-tumour 
drugs and the discovery of the effects that mangiferin might have on the anti-cancer 
action of these drugs is imperative.   
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1.2 CANCER 
1.2.1 Cervical cancer 
 
Cervical cancer develops in the lining of the cervix, the lower part of the uterus that 
enters the vagina.  This condition usually develops over time.  Normal cervical cells 
may gradually undergo changes to become pre-cancerous and then cancerous.  
Cervical intra-epithelial neoplasia (CIN) is the term used to describe these abnormal 
changes.  CIN is classified according to the degree of cell abnormality.  Low-grade 
CIN indicates a minimal change in the cells and high-grade CIN indicates a greater 
degree of abnormality.  Most (80-90%) invasive cervical cancer develops in flat, scaly 
surface cells that line the cervix (called squamous cell carcinomas).  Approximately 
10-15% of cases develop in glandular surface cells (called adenocarcinomas) (Bosch 
et al. 2002 and Garland, 2003).  
 
Cancer of the cervix is common in women worldwide and is a leading cause of 
cancer-related death in women in under-developed countries.  Worldwide, 
approximately 500 000 cases of cervical cancer are diagnosed each year, although 
routine screening has decreased the incidence of invasive cervical cancer.  Invasive 
cervical cancer is more common in women middle aged and older and in women of 
poor socio-economic status, who are less likely to receive regular screening and early 
treatment.  There is also a higher rate of incidence among African American, 
Hispanic, and Native American women (Bosch et al. 2002 and Garland, 2003).   
 
The cause of cervical cancer is unknown.  Infection with two types of human 
papilloma virus (HPV), which is transmitted sexually, is strongly associated with 
cervical and vulvar cancer and is the primary risk factor.  Evidence of HPV is found 
in nearly 80% of cervical carcinomas.  Human immunodeficiency virus (HIV) 
infection reduces the immune system’s ability to fight infection (including HPV 
infection) and increases the likelihood that pre-cancerous cells will progress to cancer.  
Women who smoke are twice as likely to develop cervical cancer, since chemicals in 
cigarette smoke may increase the risk by damaging cervical cells.  Other risk factors 
include age (the condition is rare in women younger than age 15) and race (invasive 
cancer rates are higher in African Americans, Hispanics, and Native Americans).  
Sexual activity that increases the risk for infection with HPV and HIV and for cervical 
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cancer includes the following: (i) having multiple sexual partners or having sex with a 
promiscuous partner; (ii) history of sexually transmitted disease (STD) and (iii) sexual 
intercourse at a young age (Bosch et al. 2002 and Garland, 2003).  
 
Cisplatin was found to be cytotoxic to the cervical cancer cell line, HeLa.  A cisplatin-
resistant HeLa variant cell line, which also exhibits cross-resistance to UV radiation 
and an enhancement in repair of UV-DNA adducts, has been found and therefore the 
development of novel drugs for the treatment of cervical cancer is necessary (Chao, 
1994).  The HeLa cell line was first isolated from the cervix of a 31 year old black 
female and is an adenocarcinoma cell line. 
 
1.2.2 Breast cancer 
 
Breast cancer is malignant abnormal cell growth in the breast.  Cancer cells may 
spread to other areas of the body (called metastasis).  Fibrocystic changes (e.g., 
formation of cysts, scar tissue) may cause benign lumps in the breast.  Breast cancer is 
the second most common type of cancer and the fifth leading cause of cancer-related 
deaths.  Approximately 200 000 women in the United States are diagnosed with breast 
cancer each year, and the disease causes about 40 000 deaths annually.  The incidence 
of breast cancer rises after age 40.  The highest incidence (approximately 80% of 
invasive cases) occurs in women over age 50 (Tryggvadottir et al. 2003 and 
Rogozinska-Szczepka et al. 2004). 
.   
Most breast cancer develops in glandular tissue and is classified as adenocarcinoma.  
The earliest form of the disease, ductal carcinoma in situ (DCIS), develops solely in 
the milk ducts.  The most common type of breast cancer, invasive ductal carcinoma 
(IDC), develops from DCIS, spreads through the duct walls, and invades the breast 
tissue.  Most women who develop breast cancer have no identifiable risk factors other 
than their gender.  The condition is 100 times more common in women.  The growth 
of breast cancer tumours is often affected by the presence of oestrogen and 
progesterone.  The following risk factors result from exposure to these hormones: (i) 
age (over age 50); (ii) first pregnancy after age 30; (iii) long-term (more than 5 years) 
hormone replacement therapy (HRT); (iv) menstruation before age 12; (v) menopause 
after age 50; and (vi) nulliparity (never gave birth).  Other risk factors include the 
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following: (i) family history of the disease; (ii) genetic link; (iii) history of breast 
biopsy or radiation to the chest; (iv) moderate alcohol use (2 to 5 drinks daily); (v) 
obesity; (iv) personal history of the disease (women with a history of breast cancer are 
3 to 4 times more likely to have a recurrence); (v) race (slightly more common in 
Caucasians); and (vi) sedentary lifestyle (Tryggvadottir et al. 2003 and Rogozinska-
Szczepka et al. 2004). 
 
Approximately 5% of breast cancer cases have a genetic link that results from an 
inherited mutation in genes identified as BRCA1 and BRCA2.  Patients who inherit 
an altered BRCA1 or BRCA2 gene have an increased risk for developing pre-
menopausal breast cancer and are more likely to have family members with the 
condition.  The breast cancer cell line, MCF7, was isolated from the mammary gland 
(breast), of a 69-year-old Caucasian female and is an adenocarcinoma cell line 
(Rogozinska-Szczepka et al. 2004). 
 
1.2.3 Colon cancer 
 
The colon and rectum are part of the digestive tract.  Together, they comprise the 
large intestine, which is located in the abdomen between the small intestine and the 
anus.  Cancer that originates in the colon or rectum is called colorectal cancer.  The 
colon absorbs water, electrolytes, and nutrients from food and transports them into the 
bloodstream.  Most (over 95%) colorectal cancers are adenocarcinomas that develop 
when a mutation occurs in cells that line the wall of the colon or rectum.  The disease 
often begins as an intestinal polyp, also called an adenoma, which is an abnormal 
growth of tissue.  Polyps gradually can become pre-cancerous and then cancerous.  
Incidence of colorectal cancer is highest in developed countries such as the United 
States and Japan, and lowest in developing countries in Africa and Asia.  According 
to the American Cancer Society, it is the third most common type of cancer in both 
men and women in the United States.  Incidence is slightly higher in men than 
women, and is highest in African American men.  The death rate from colorectal 
cancer has declined over the past 15 years due to improved screening methods and 
advances in treatment.  However, the emergence of cisplatin-resistant colon 
carcinoma cell lines (eg. HT29) necessitates the development of novel drugs for the 
treatment of colon cancer (Venook, 2005). 
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The efficiency of cisplatin is low in colorectal cancer, with fewer than 20% clinical 
responses when used alone or in combination.  Oxaliplatin is clinically active in 
metastatic colorectal cancer.  However, an acquired resistance to oxaliplatin always 
develops after a few months of treatment.  Hence, the development of novel drugs for 
the treatment of colorectal cancer is also imperative (Sergent et al. 2002).  The HT29 
cell line was isolated in 1964, is an adenocarcinoma cell line and the cells are 
distributed for research purposes only. 
 
1.3 METAL COMPLEXES IN MEDICINES 
 
Most of the main classes of pharmaceutical agents contain examples of metal 
compounds that are currently used clinically; moreover, new areas of use are fast 
emerging.  Targeting is vital, because of the toxicity often associated with metal 
compounds.  If they can be delivered only to the tissues, cells and receptors where 
they are required, the toxicity may be reduced.  The ease with which many metal 
complexes undergo ligand substitution and redox reactions might mean that the active 
species are biotransformation products of the administered complex.  Identification of 
these active species may lead to the more effective use of metal compounds as drugs 
(Sadler and Guo, 1998). 
 
1.3.1 Platinum anticancer agents 
 
1.3.1.1 Some basic chemistry 
 
In order to obtain insight as to how the interaction of a metal, such as platinum, can 
achieve anticancer results, it is necessary to briefly review the most important 
properties of the metal. 
(i) Ligand preferences 
Pt is a typical later 5d transition metal, which forms highly covalent bonds with 
N and S donor atom ligands, like aliphatic and aromatic amines and thiols, 
thioethers, thiocarbamates, etc.  Its compounds are kinetically stable (relatively 
slow ligand exchanges) and thermodynamically stable with the above-mentioned 
ligand types (Wilkinson, 1987).   
(ii) Ligand exchange rate 
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Pt(II) has the potential to form a stable bond with N donor ligands in the DNA 
helix, thus preventing DNA replication and promoting cell death.  
The ligand exchange is controlled by the “trans effect” which is the effect of a 
coordinated ligand on the rate of replacement of a ligand trans to it.  A sequence 
of trans effectiveness is: H2O <NH3 ~ amines < Cl- ~ Br- < SCN- ~ I- ~ NO2- < 
SC(NH2)2 < thioethers < CN-.  This behaviour relates directly to the anticancer 
action of Pt(II) since neither too fast exchange nor too slow exchange is required 
for optimal action (Tobe, 1972).  
(iii) Coordination chemistry 
Platinum (II) is almost without exception found in a square planar symmetry.  It 
can exist in either a cis or trans complex form.  
 
Pt
Cl Cl
NH3NH3
Pt
Cl NH3
ClH3N
cis trans  
The anions are normally the “leaving groups” which implies that they can 
readily be replaced.  Exchange of bidentate anions, like dicarboxylate ions, are 
slower than e.g. oxalate and malonate, like Cl-, as a result of an entropy 
contribution to their stability.  Ligand exchange occurs via two mechanisms; 
firstly by an SN2 mechanism, i.e. through the formation of a five coordinated 
activated intermediate species (either square-pyramidal or trigonal 
bipyramidal) or, secondly, by an SN1 mechanism, i.e. through bond-breaking 
and thus the formation of a three coordinated intermediate species.  The first 
mechanism (SN2) is the most likely to occur since it is normally energetically 
easier.  Complexation of the Pt(II) with ligands which are bulky in the vicinity 
of the donor atom can avoid the formation of a five-coordinated species and 
thus force the mechanism to an SN1 mechanism.  This will lead to slower 
ligand exchange. The stability of square planar complexes as compared to 
higher coordination, e.g. five-coordination is an important parameter in 
controlling ligand exchange, since an important mechanism by which it occurs 
is via a five-coordinated intermediate.  Ligand exchange can also be slowed 
down by stereochemical crowding of Pt(II) in the complex which will suppress 
 10 
the formation of the above mentioned intermediate form (Wilkinson, 1987 and 
Tobe, 1972).  
(iv) Hydrophobicity  
Hydrophobicity of the Pt(II) complex is a further significant parameter, e.g. in 
the case of an organic amine donor with an alkyl or aryl “tail end”, cell 
membrane transport is promoted and thus uptake of the complex (Hambley, 
1997).  
(v) S donor ligands 
The interaction, with the anticancer agent, of S donor ligands present in the 
biological fluid, more specifically thiols (like glutathione and cysteine) is 
important.  Thiols normally bond irreversibly to Pt(II) under the conditions 
prevailing in body fluids (pH≅neutral), thus rendering the Pt(II) agent inert and 
ineffective for anticancer action.  Whereas an N7 atom of guanine can replace a 
thioethereal S atom from a Pt(II) complex, it cannot do so with a thiolate ion 
RS-.  
Thioethers react as follows with Pt(II) compounds:  
Pt
Cl
Cl
ClCl Pt
Cl
Cl
SR2Cl
2-
+  RSR
-
+  Cl-
 
 namely through a neutral sulphur.  The reaction is however reversible.  Thiols 
react as follows with Pt(II) compounds: 
 
 
 
  
 
 
The rate of the thiol reaction is much slower than that of the thioether (like 
methionine) i.e. deprotonation of the thiols occurs due to the strong Pt-S 
interaction and simultaneous weakening of the S-H bond.  Thus, amounting to 
changing of the neutral HSR compound into a thiolate ion (-SR).  The very 
strong trans-directing capability of the –SR group does not allow strong bonding 
Pt
Cl
Cl
ClCl Pt
Cl
Cl
SRCl
2-
+  HSR
2-
+  HCl
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trans to it, except by another –SR group, thus reducing anticancer action.  The 
space-filling models depicted in figure 1.1 shows the relatively large size of 
thiol sulfur which acts as a strong donor towards Pt(II) as described in the text.  
The above compounds can act as detoxifying agents against the platinum agents 
(Bierbach et al. 1998 and Reedijk, 1999).  
 
 
  
S
N
N
H
H
H
H
H
H
C
C
C
O O
O
 
    A      B 
 
Figure 1.1: The space-filling models of two sulfur containing biomolecules (A) 
Cysteine and (B) Glutathione.   
 
(vi) Biocompatibility 
The platinum compounds should have significant solubility in body fluid.  
Solubility should conveniently be between 10 and 100 µM (Los et al. 1996). 
(vii) Mode of bonding 
In general, the cis-compounds are the most effective anticancer agents, e.g. 
cisplatin is much better than transplatin.  It is interpreted that the cis complex 
can form intramolecular adducts with N atoms in the helix much more readily 
than the trans complex.  These result in a kind of chelate adduct that is 
kinetically and thermodynamically more stable and can thus more readily cause 
cell death.  The space-filling models of two important nucleotide bases, adenine 
and guanine (Figure 1.2), show that the N7 atom of the guanine is more 
“exposed” or lesser crowded than the corresponding N7 atom of the adenine.   
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    A     B 
 
Figure 1.2: The space-filling models of two important nucleotide bases (A) Adenine and 
(B) Guanine.   
The result is that the former acts as a stronger ligand towards Pt(II) than the 
latter.  For example, the guanine N7 atom can replace a thioethereal sulfur atom 
bonded to platinum, whereas that of adenine cannot (Jamieson and Lippard, 
1999). 
(viii) Stereochemistry 
The influence of stereochemistry in relation to the control of kinetics of ligand 
exchange is not the only result of stereochemical crowding of these agents.  The 
role of the “organic bulk” of the ligands bonded to the platinum has also been 
related to an interaction mode with the major groove of the helix, in a fashion 
that promotes the bonding of the complex to the helix.  Evidence for such 
interaction came from 1,2-diaminocyclohexane compounds such as oxaliplatin 
(Scheeff et al. 1999).  
 
1.3.1.2 
 
Novel complexes 
In the design of novel anticancer agents all the above factors had to be considered.  It 
was decided by The Research Unit for Platinum Group Chemistry to concentrate on 
novel diamines and N-S chelates (S=thioether groups) as “non-leaving” groups.  The 
structures were varied to allow for different stereochemical interactions and 
hydrophobicity.  For “leaving groups” chloride and dicarboxylate anions were used.  
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Pt
N
N
X
X
Pt
N
S
X
X
X=anion  
N-N and N-S signifies bidentate chelate ligands forming five-membered ring 
complexes with Pt(II) and X=monoanionic species.  The latter could be replaced by 
dianionic species. 
 
1.3.1.3 
 
Important biochemical aspects 
Platinum(II) complexes are amongst the most extensively used drugs for the treatment 
of cancer.  Three injectable diammine compounds have been approved for clinical 
use.  These include cisplatin, carboplatin and 254-S (Figure 1.3).  Several others are 
undergoing clinical trials.  Studies on reducing the toxicity of platinum anticancer 
complexes towards normal cells, evading acquired resistance to cisplatin, and 
increasing the spectrum of activity of platinum complexes towards a wider range of 
types of cancer, are important research fields.  Other cisplatin analogues include 
oxaliplatin, nedaplatin, loboplatin, ZD0473, oxoplatin and Se-Pt conjugate (Figure 
1.3) (Sadler and Guo, 1998 and Wozniak and Blasiak, 2002). 
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  A   B   C 
 
    D   E 
 
F   G   H 
Figure 1.3: The three injectable diammine compounds that have been approved for clinical use;  
(A) Cisplatin, (B) Carboplatin, (C) 254-S (nedaplatin) (Sadler and Guo, 1998) and 
the structures of the cisplatin analogues; (D) lobaplatin, (E) ZD0473, (F) oxoplatin, 
(G) Se-Pt conjugate and (H) oxaliplatin (Wozniak and Blasiak, 2002). 
 
The decisive target for Pt is DNA and certain platinated DNA adducts trigger DNA 
degradation and apoptosis (programmed cell death) (Sadler and Guo, 1998).   
 
1.3.2 
 
Other complexes 
Bismuth(III) compounds, such as bismuth subcitrate and subsalicylate, are commonly 
used for the treatment of diarrhoea, dyspepsia and gastric and duodenal ulcers.  Bi(III) 
is active against the bacterium Helicobacter pylori, which is associated with the 
mucus layer of ulcers (Sadler and Guo, 1998). 
 
Injectable Au(I) thiolate drugs such as aurothiomalate (Myocrisin), aurothioglucose 
(Solganol), and aurothiopropanol sulfonate (Allochrysin), and the oral drug 
auranofin (Ridaura), are widely used for the treatment of difficult cases of 
rheumatoid arthritis.  Gold(I) has a much higher affinity for thiolate S compared to 
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thio-ether S, and a much lower affinity for N and O ligands.  Consequently Au(I) 
binds to DNA very weakly and is not usually carcinogenic or mutagenic.  Thiolate 
exchange reactions on Au(I) occur effortlessly and therefore the administered drugs 
are probably not the pharmacologically active species (Sadler and Guo, 1998).  
 
1.4 CISPLATIN 
 
Cisplatin belongs to the group of medicines known as alkylating agents and is 
chemotherapy that is given as a treatment for some types of cancer.  It is 
predominantly used to treat testicular, bladder, lung, oesophagus, stomach, and 
ovarian cancers.  It is a clear fluid, which is given as an infusion into the vein through 
a cannula as a sterile saline solution.  It may be administered through a central line 
(inserted under the skin into a vein near the collarbone), or a line inserted into a vein 
in the crook of the arm.  The dose of cisplatin will be different for different patients, 
since it may depend on a number of things, including what the medicine is being used 
for, the patient’s size, and whether or not other medicines are also being taken.  If a 
combination of medicines is administered to a patient, it is extremely important that 
the patient receives each one at the proper time.  Single Agent Therapy may include: 2 
to 3 mg/kg every 3 to 4 weeks, 20 mg/m2/day for 5 days every 3 to 4 weeks, 100-120 
mg/m2 every 3 to 4 weeks or 80 mg/m2 (24 hour infusion) every 3 to 4 weeks (Lidor et 
al. 1993). 
 
1.4.1 Mechanism of action 
Cisplatin coordinates to DNA and this coordination complex not only inhibits 
replication and transcription of DNA, but also leads to programmed cell death 
(apoptosis).  Apoptosis is an actively performed cellular suicidal process, which is 
essential for development and maintenance of tissue homeostasis of multicellular 
organisms.  Prominent morphological features such as membrane blebbing, nuclear 
condensation, DNA fragmentation and apoptotic body formation characterise it.  
Caspases, which belong to the family of cysteine proteases, play a crucial role in the 
implementation of apoptosis.  Caspases are synthesized as inactive zymogens, which 
become activated by cleavage after a specific aspartate residue within a linker domain 
between a large subunit (LS) and a small subunit (SS), in addition to cleaving off of 
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the NH2-terminal pro-domain.  The LS and SS subsequently combine to form active 
caspases.  When cells receive death signals, a subset of caspases is activated in a 
structured fashion and directs the processing and activation of critical effector/ 
executioner caspases (Araya et al. 2002).   
 
Apoptosis has three different stages (Figure 1.4).  The first is an initiation phase, in 
which a stimulus is received, followed by engagement of any of several possible 
pathways that respond to the stimulus.  The effector phase is the second stage.  During 
this phase all the possible initiating signals are integrated and a “decision” to live or 
die is made.  The last stage is the common irreversible execution phase, during which 
some proteins autodigest and DNA is cleaved.   
 
Bcl-2 is an oncogene that seems to be at the convergence of many apoptotic pathways 
and the ratio of Bcl-2 to Bax protein might be the final determinant of whether a cell 
enters the execution phase.  Bax is a gene that encodes a dominant inhibitor of Bcl-2.  
A conserved feature of the execution phase of apoptosis is the specific degradation of 
a series of proteins by the cysteine-aspartate-specific proteases, or caspases.  Caspases 
are activated when an apoptotic stimulus induces the release of cytochrome c from 
mitochondria.  (Gonzalez et al. 2001).  The caspases most often coupled with 
programmed cell death are caspases 2, 3, 6, 7, 8, 9 and 10.  Caspase cascades contain 
upstream (initiator) caspases (caspase 2, 8 and 10), which are activated by death 
receptor signalosomes; caspase 9, which is activated by the mitochondrial cytochrome 
c/Apaf-1 derived apoptosome and downstream (effector) caspases (caspase 3, 6 and 7) 
that cleave the proteins involved in apoptosis.  Caspase 2, 8 and 10 are activated by 
death receptor signalosomes (death-inducing signaling complex (DISC)).  In addition 
caspases 8 or 10 activates pro-apoptotic factors such as BID that induce the release of 
cytochrome c from the mitochondria or activates caspase-3, 6 or 7 directly.  The 
mitochondrial release of cytochrome c activates Caspase 9 and the cytosolic 
cytochrome c binds and induces oligomerization of apoptotic protease activating 
factor 1 (APAF-1) followed by recruitment of procaspase-9 to form an apoptosome.  
Apoptosome-associated procaspase-9 self-activates and then activates the downstream 
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caspase 3 and/ or 7.  These downstream executioner caspases (3, 6, and 7) in turn 
cleave numerous proteins, enzymes and signalling molecules (Khosravi-Far and 
Esposti, 2004 and Wajant, 2003). 
 
Figure 1.4: Scheme of the converging pathways leading to apoptosis in mammalian cells. A great 
variety of stimuli, such as depletion of survival signals, death signals, physical and 
chemical agents, and loss of cell-cell contacts, can initiate apoptosis through 
numerous different means. The effector phase integrates these signals leading to the 
decision of life or death.  (PDGF, platelet-derived growth factor; TNF, tumour 
necrosis factor; CDDP, cisplatin, bFGF, basic fibroblast growth factor; FasL, Fas 
ligand) (Gonzalez et al. 2001). 
 
The efficacy of cisplatin in the clinic is restricted in several ways.  These include the 
spectrum of its anticancer activity, since it is not active enough against several types 
of cancer, the development of resistance after continued treatment, and its high 
toxicity to some normal cells (Sadler and Guo, 1998). 
 
Formation of any platinated coordination complex with DNA is not adequate for 
cytotoxic activity.  The corresponding trans isomer of cisplatin (namely, trans-DDP) 
also forms a coordination complex with DNA but in contrast to cisplatin, trans-DDP 
is not an efficient chemotherapeutic agent.  Due to the difference in geometry between 
cis- and trans-DDP, the types of coordination complexes formed by the two 
compounds with DNA are different.  These differences are critically important in 
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determining the value of a particular compound for the treatment of cancer.  Cisplatin 
also binds to plasma and cellular proteins which is responsible for the difficulty in 
clearing it from the circulation and tissue.  It binds irreversibly to sulfhydryl groups of 
low- and high-molecular- weight molecules, which correlates with a fall in the 
concentration of sulfhydryl moieties in the kidney, especially in the mitochondrial and 
cytosolic fractions.  This causes the inhibition of a number of sulfhydryl-containing 
enzymes (including ATPases, thymidylate synthetase, glyceraldehyde-3-phosphate 
dehydrogenase, glucose-6-phosphate dehydrogenase, γ-glutamylcysteine synthetase, 
and ribonucleotide reductase).  The depletion of sulfhydryl groups, which include 
glutathione, may alter the redox state and contribute to cisplatin-induced cytotoxicity.  
Thus the toxicity of cisplatin may be due to a combination of factors that include, but 
may not be restricted to, DNA cross-linking, inhibition of enzymatic activity, and 
depletion of the antioxidant pool (Jordan and Carmo-Fonseca, 2000 and Sheihk-
Hamad, 2008). 
 
The sterile saline solution in which cisplatin is administered contains sodium chloride.  
When cisplatin enters the bloodstream, it remains intact due to the relatively high 
concentration of chloride ions.  The neutral cisplatin enters the cell by passive 
diffusion or alternatively via active uptake by the cell.  Once inside the cell, the 
molecule undergoes hydrolysis, due to a much lower concentration of chloride ions, 
and a molecule of water replaces a chloride ligand.  Hence a positively charged 
species is generated (Figure 1.5).  The reaction occurring is as follows:  
 
Pt(NH3)2Cl2 + H2O → [Pt(NH3)2Cl(H2O)]+ + Cl- 
[Pt(NH3)2Cl(H2O)]+ + H2O → [Pt(NH3)2(H2O)2]2+ + Cl- 
 
(Jordan and Carmo-Fonseca, 2000 and Helm and States, 2009). 
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Figure 1.5: The cellular uptake of cisplatin and its targets (http://chemcases.com/cisplat/) 
 
Cisplatin has a number of possible targets once inside the cell (Figure 1.5).  These 
include DNA, RNA, sulfur-containing enzymes (metallothionein and glutathione), 
and mitochondria.  The effects of cisplatin on mitochondrial DNA are not well 
understood, but there is a possibility that damage to mitochondrial DNA that results 
from treatment with cisplatin, contributes to cell death.  The interaction of cisplatin 
with sulfur-containing enzymes is better understood and is thought to be involved in 
the resistance of cells to cisplatin.  The effects of cisplatin on RNA and DNA have 
been studied extensively.  Although cisplatin can coordinate to RNA, this interaction 
is not thought to play a significant role in cisplatin’s mechanism of action in the body.  
The reasons for this are (i) a single damaged RNA molecule can be replaced by newly 
synthesized material and studies have shown that cisplatin does not affect RNA 
synthesis (DNA synthesis is affected) and; (ii) when cisplatin was administered in 
vitro at its lethal dose to a strain of cancer cells, only a small fraction (1% to 10%) of 
RNA molecules were damaged.  Cisplatin coordinates to DNA primarily through 
certain nitrogen atoms of the DNA base pairs.  These nitrogen atoms (in particular, 
the N7 atoms of purines) are free to coordinate to cisplatin, since they do not form 
hydrogen bonds with any other DNA bases (Figure 1.6) (Perez, 1998 and Helm and 
States, 2009). 
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Figure 1.6: The DNA base pairs.  Cisplatin coordinates to the N7 atoms of the purine (guanine 
and adenine) bases (http://chemcases.com/cisplat/). 
 
Numerous types of cisplatin: DNA coordination complexes, or adducts, may be 
formed.  The most significant of these appear to be the ones in which the two chlorine 
ligands of cisplatin are replaced by purine nitrogen atoms on adjacent bases on the 
same strand of DNA; these complexes are referred to as 1,2-intrastrand adducts.  The 
purine bases most frequently involved in these adducts are guanines; however, 
adducts involving one guanine and one adenine is also found.  The formation of these 
adducts causes the purines to become de-stacked and the DNA helix to become 
kinked (Figure 1.7) (Petit et al. 2003 and Voland et al. 2006).   
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   A     B 
Figure 1.7: (A) The structure of cisplatin coordinated to a dinucleotide containing two guanines. 
The guanine bases, which would normally be parallel to one another, are de-stacked.  
(B) The structure of cisplatin coordinated to two guanines in a DNA duplex 
(http://chemcases.com/cisplat/). 
 
Cisplatin begins its interaction with cancer DNA by binding to the nitrogen atoms of 
the DNA bases, typically guanine.  Approximately 90% of cisplatin-DNA adducts are 
1,2 intrastrand cross-links, of which about 65% are two adjacent N7 guanine sites and 
about 25% are two adjacent N7 guanine-N7 adenine sites.  The high occurrence of 
intrastrand adducts is due to the shortest distance between two N7 atoms.  The 
remaining adducts are comprised of interstrand cross-links and monofunctional 
cisplatin adducts.  Due to conformational constraints, bi-functional adducts are 
formed only in purines that are adjacent or directly across (not more than one base 
pair apart) from each other (Figure 1.8) (Wozniak and Blasiak, 2002; Gonzalez et al. 
2001 and Siddik, 2003).  
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  A      B 
Figure 1.8: (A) Schematic representation of cisplatin adducts.  The platinated nucleosides are 
underlined (Wozniak and Blasiak, 2002).  (B) The main adducts formed in the 
interaction of cisplatin with DNA. (a) interstrand cross-link; (b) 1,2-intrastrand cross-
link; (c) 1,3-intrastrand cross-link and; (d) protein-DNA cross-link (Gonzalez et al. 
2001). 
 
These cisplatin adducts aid in destabilization of the DNA.  Cisplatin binding severely 
distorts DNA by twisting, unwinding, and shortening the duplex.  It causes significant 
bending of about 40° away from the site of attachment.  Although the overall structure 
of the double helix remains intact, the distortion is absorbed by conformational 
changes in the sugar-phosphate backbone near the platinum lesion.  This propagates 
steric constraints that lead to a loss in helix stability.  (Siddik, 2003; Scheeff et al. 
1999).   
 
Trans-DDP is less active than cisplatin.  Due to its geometry, it cannot form a 1, 2-
intrastrand adduct with DNA.  Hence, the 1, 2-intrastrand adducts, formed between 
cisplatin and DNA, are believed to be vital for anticancer activity of cisplatin.  It has 
been found that this binding affects both replication and transcription of DNA, as well 
as mechanisms of DNA repair.  The effects of cisplatin and trans-DDP on DNA 
replication were studied both in vitro and in vivo.  In vitro studies on prokaryotic and 
eukaryotic cells showed that DNA adducts of both cisplatin and trans-DDP blocked 
the action of DNA polymerase, which is necessary for replication.  The presence of an 
 23 
adduct alters the alignment of DNA thus altering the binding site for DNA 
polymerase, an important enzyme for DNA synthesis.  This in turn slows down the 
protein conformational change necessary for polymerisation of that specific portion.  
The binding of the next correct nucleotide is therefore affected.  Polymerases are able 
to bypass cisplatin adducts only approximately 10% of the time.  Likewise, in vivo 
studies showed that cisplatin and trans-DDP inhibited replication equally well.  Since 
studies have shown that cisplatin is an effective antitumour agent but trans-DDP is 
not, these results suggest that DNA replication is not the only factor important for the 
clinical activity of cisplatin in the destruction of cancer cells.  The effects of cisplatin 
and trans-DDP on DNA transcription are more difficult to interpret than the effects on 
replication.  However, cisplatin does not appear to inhibit transcription (Scheeff et al. 
1999 ).   
 
The cytotoxic activity of cisplatin may arise from the cells’ inability to repair DNA 
damage caused by cisplatin.  In vitro studies on cell extracts suggested that the most 
common 1,2-intrastrand cisplatin: DNA adducts are not readily repaired by the 
excision repair system.  Researchers have conducted additional studies to address the 
likelihood that cisplatin’s cytotoxic activity may result from a failure of the excision 
repair system.  This repair system relies on the fact that, before the damaged portion 
of DNA is even excised from the rest of the strand, the cell must recognize it.  The 
cell detects DNA damage by the action of damage recognition proteins.  Hence, 
evidence of proteins attached to cisplatin: DNA adducts were looked for.  Several 
proteins that bind to cisplatin: DNA adducts were isolated and these proteins all 
contain a portion of similar or even identical sequences of amino acids, called a high 
mobility group (HMG).  The proteins in this class are called HMG-domain proteins.  
It has been shown that HMG-domain proteins bind cisplatin: DNA adducts in vitro.  
In vivo assays on yeast have also provided confirmation that HMG-domain proteins 
are important for the activity of cisplatin, since cells lacking the gene that codes for 
HMG-domain proteins are less sensitive to cisplatin than cells containing the gene.  
Hence, cisplatin is less effective in killing these cells (Jordan and Carmo-Fonseca, 
2000).   
 
Two theories explain the possible role of HMG-domain proteins in cisplatin’s 
cytotoxic activity.  Various HMG-domain proteins are transcription factors, and are 
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thus required for the synthesis of RNA from a DNA template.  The first theory claims 
that if HMG-domain-containing transcription factors bind preferentially to the 
cisplatin: DNA adducts, they could interfere with the transcriptional machinery, most 
probably leading to cell death.  The second theory asserts that when HMG-domain 
proteins bind to the cisplatin: DNA adducts, these adducts would not be recognized by 
the repair machinery and DNA repair would then be slower than normal (Figure 1.9) 
(Huang et al. 1994). 
 
Figure 1.9: Model for the inhibition of cisplatin adduct repair in the presence of HMG-domain 
proteins (http://chemcases.com/cisplat/). 
 
1.4.2 Toxic side-effects 
 
Cisplatin interferes with the growth of cancer cells, which are ultimately destroyed.  
Since the growth of normal body cells may also be affected by cisplatin, other effects 
will inevitably also occur.  Each person's reaction to chemotherapy is unique.  Some 
people have very few side effects, while others may experience more.  Some of the 
more common side effects include:  (i) Nausea and vomiting, for which there are now 
very effective anti-sickness drugs to prevent or greatly reduce it.  If they do occur they 
may begin a few hours after the treatment is given and last for up to a few days.  (ii) 
The kidneys may be affected by cisplatin treatment.  Usually this does not cause any 
symptoms, and the effect is mild, but if the effect is severe the kidneys can be 
permanently damaged unless the treatment is stopped.  Therefore the kidneys will be 
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checked by a blood test before each treatment.  Plenty of fluid will be given 
intravenously before and after the treatment to support normal kidney functions. 
The less common side effects include:   
(i) Temporary reduction in the production of blood cells by the bone marrow.  
This can result in anaemia leading to tiredness; an increased risk of 
bruising or bleeding and an increased risk of infection.  This effect can 
begin from seven days after the treatment has been given and the number 
of blood cells may be at its lowest at 10-14 days after the chemotherapy.  
The bone marrow gradually returns to normal within 21-28 days.  The 
extent to which blood cells are reduced depends on the dose of 
chemotherapy and which other chemotherapy drugs, if any, are given in 
combination.  Hence, a patient’s blood should be monitored regularly 
(Ozturk et al. 2005).     
(ii)  Numbness or tingling in hands or feet may occur.  This is due to the effect 
of cisplatin on nerves and is known as peripheral neuropathy.  A patient 
may notice that they have difficulty doing up buttons or performing similar 
tasks.  This side effect usually disappears slowly a few months after the 
treatment ends.  Peripheral sensory neuropathy develops in the majority of 
patients treated with cumulative doses of cisplatin higher than 300 mg/m2.  
The pathology involves primary sensory neurons of dorsal root ganglia as 
well as peripheral glial cells.  Gill and Windebank, (1998) believed that 
neuropathy may arise secondary to renal failure during treatment with 
cisplatin, but it was shown that it is unlikely that the neuropathic findings 
(in a study by Ozturk et al. (2005)), were due to renal toxic side-effects, 
since none of the mice in this study showed signs of significant tissue 
damage in the kidney sections (Ozturk et al. 2005).   
(iii) Ototoxicity (changes in hearing) may occur.  Cisplatin and carboplatin are 
highly effective chemotherapeutic agents with ototoxic side effects that 
limit their efficacy.  Formation of reactive oxygen species (ROS) in 
CDDP-exposed cochlear tissues is involved in ototoxic action of the 
CDDP on hair cells (Eshraghi et al. 2006). A patient may experience 
tinnitus (ringing in the ears) and may lose the ability to hear some high-
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pitched sounds.  Again, this effect usually decreases when the treatment 
ends, although, in a small number of cases, it may be permanent.  Animal 
models have suggested an important role of reactive oxygen species (ROS) 
in the pathophysiology of cisplatin-induced ototoxicity.  The activity of 
anti-oxidative enzymes undergoes changes following cisplatin exposure, 
and various radical scavengers and antioxidants protect against hearing 
loss in animals in vivo.  It has been shown that there is significant loss of 
outer hair cells in the region of the cochlea of mice after exposure to 
cisplatin and that cisplatin reduces the amount of total antioxidant in 
cochlear tissue (Minami et al. 2004).   
(iv) Temporary taste alterations may occur.   
(v) Patients may experience a loss of appetite.   
(vi) Diarrhoea may occur as a side-effect to cisplatin treatment and this can 
usually be easily controlled, but it is important to drink plenty of fluids if 
this side-effect occurs; and  
(vii) Patients may experience allergic reactions.  Signs of an allergic reaction 
include skin rashes and itching, a high temperature, shivering, redness or 
darkening of the face, dizziness, a headache, breathlessness, anxiety and a 
diuretic effect (www.chemocare.com).   
1.4.3 Cisplatin resistance 
 
Cisplatin is one of the most widely used chemotherapeutic drugs for the treatment of 
cancer.  Initially, platinum-based therapies are very efficient in treating a wide range 
of cancers; however, recurrence and resistance remain the foremost limitation to 
curative therapies.  Various mechanisms of resistance have been proposed, including 
reduced drug concentration in the cell, drug inactivation, increased DNA repair, or 
failure to turn on cell death pathways (Min et al. 2004).   
 
Although cisplatin resistance is clearly multifactorial in nature, increased levels of 
cellular thiols are often associated with the cisplatin-resistant phenotype.  Cellular 
thiols, including glutathione (GSH), can sequester cisplatin, leading to a reduction in 
the levels of cisplatin–DNA damage.  DNA is the therapeutic target of cisplatin, and 
efficacy is a function of cisplatin–DNA adducts inhibiting DNA replication and 
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transcription, eventually resulting in apoptosis.  Reduced efficacy of the cisplatin is 
often observed in cells with increased GSH levels. Modulating the levels of 
intracellular thiols has been demonstrated to influence cisplatin cytotoxicity in 
numerous studies (Turchi, 2006).  In human ovarian carcinoma cell lines, it was found 
that resistance to cisplatin was accompanied by cross-resistance to copper.  These 
results were consistent with the concept that cisplatin enters and exits the cell via 
transporters that normally mediate copper homeostasis (Katano et al. 2002).  
However, despite numerous studies, the understanding of resistance to this widely 
used drug remains poor, and the signalling pathways that activate the variety of 
proposed mechanisms of resistance are largely unknown (Min et al. 2004).   
 
Platinum resistance mechanisms can be grouped into two main groups.  The first is 
those that limit the formation of cytotoxic platinum-DNA adducts and the second 
those that prevent cell death from occurring after platinum-DNA adduct formation.  
Group I includes decreased drug accumulation and increased drug inactivation by 
cellular protein and non-protein thiols.  Group II includes increased platinum-DNA 
adduct repair and increased platinum-DNA damage tolerance.  Multidrug resistance 
protein (MRP) is a member of a family of transport proteins that facilitates the 
transport of a variety of glutathione-coupled and unmodified drugs out of cells.  
However, the over-expression of MRP alone does not confer resistance.  (Helm and 
States, 2009).  
 
The ability of cancer cells to become cross-resistant to structurally and functionally 
unrelated anti-cancer drugs is an event known as multidrug resistance.  The incidence 
of multidrug resistance depends on the type of tumour, treatment status and other 
factors.  Factors that affect response to anti-cancer chemotherapy are cell kinetic, 
pharmokinetic and cellular drug resistance mechanisms (Table 1.1).  Some 
mechanisms of cellular drug resistance that occur at a molecular level include: (i) 
reduction of the intracellular accumulation of anti-cancer drugs by either increasing 
drug efflux and/ or decreasing drug uptake; (ii) sequestration of drugs; (iii) alterations 
in drug targets or (iv) activation of detoxifying systems, such as glutathione/ 
glutathione-S transferases.  Other factors that may play a role in multidrug resistance 
include increased repair of drug-induced DNA damage, blocked apoptosis, disruptions 
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in signalling pathways and alterations of factors involved in cell cycle control 
(Filipits, 2004). 
 
Table 1.1: Mechanisms of drug resistance (Filipits, 2004). 
 
Mechanism Individual process 
Cell kinetic resistance Tumour growth 
Pharmacokinetic resistance Poor absorption 
Excessive metabolism 
Poor penetration to certain sites 
Blood supply of the tumour 
Drug diffusion 
Cellular drug resistance Increased drug efflux 
Decreased drug uptake 
Sequestration of drugs 
Alterations in drug targets 
Activation of detoxifying systems 
Increased repair of drug-induced DNA damage 
Blocked apoptosis 
Disruption in signalling pathways 
Alterations of factors involved in cell cycle regulation 
 
Cisplatin resistance might develop due to monthly acute exposure to the drug.  This is 
generally associated with decreases in intracellular accumulation of the drug.  The 
defect in drug accumulation is usually modest, even when the level of resistance is 
quite high.  Studies of cisplatin-resistant cells with decreased drug accumulation have 
identified that membrane proteins may play a role, through either decreased or 
increased expression.  Modulation of cisplatin accumulation has been achieved by 
treatments that are thought to have membrane-fluidising effects, such as 
hyperthermia, as well as by using drugs that are membrane-active and function as 
signal transduction modulators.  Calcium channel blockers and calmodulin inhibitors 
are known for their capacity to circumvent multidrug resistance by reducing the 
increased drug efflux in cancer cells (Chao, 1996 and Helm and States, 2009). 
 
Long-term exposure to increasing concentrations of cisplatin may result in increased 
levels of glutathione (GSH) and metallothionein (MT).  GSH functions in membrane 
transport, drug inactivation and elimination by conjugation with substances, such as 
platinum containing agents (Dunfield and Guernsey, 2002).  GSH is the most 
abundant thiol in the cell, present at concentrations of 0.5 to 10mM.  It is a potent 
nucleophile and reacts with cisplatin and alkylating agents.  GSH and cisplatin react 
in a 2:1 molar ratio and form a cisplatin complex that is then eliminated from the cell 
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by an ATP-dependent GSH S-conjugate export pump; the GS-X pump.  In 
combination with GSH, GSH S-transferase (GST) may play a role in cisplatin 
resistance, since it is responsible for the conjugation of chemicals to the thiol group.  
GSH may protect cells by intercepting reactive platinum complexes before they can 
react with DNA as well as by supporting DNA repair, most probably by stabilization 
of repair enzymes, such as DNA polymerase α or by promoting the formation of 
deoxyribonucleotides.  This means that cisplatin-resistant cells usually express an 
improved radical scavenging system, such as GSH and the GS-X pump (Chao, 1996 
and Chen et al. 1998).  It has been proposed that glutathione may protect cells by 
binding to or reacting with drugs, by interacting with reactive oxygen moieties or with 
other radicals produced by radiation, by preventing damage to proteins or DNA, or by 
participating in the repair process (Godwin et al. 1992 and Helm and States, 2009).   
 
MT is a small protein that contains 20 cysteine residues; hence it exhibits a high 
affinity for metals (Choi et al. 2004).  Both transplatin and cisplatin bind to MT, at a 
ratio of 10 platinum atoms per molecule.  The binding rate constant for MT is much 
higher than for GSH.  Upon binding to MT, cisplatin loses its amine ligands and 
displaces heavy metal ions.  Mammalian MT is presumed to have a role in the 
detoxification of heavy metal ions.  Exposure of cell lines to cisplatin often has no 
effect on MT.  However, cell lines exposed to heavy metals show increases in MT and 
become cross-resistant to cisplatin (Chao, 1996; Perez, 1998 and Helm and States, 
2009). 
 
Cisplatin adducts are primarily repaired by the nucleotide excision repair pathway.  
Poor repair of d(GpG) intrastrand cross-links may contribute to cisplatin cytotoxicity.  
Cisplatin-resistant cell lines show increased levels of DNA repair (measured by the 
loss of platinum adducts), reactivation of cisplatin-damaged plasmid DNA and DNA 
repair synthesis.  Studies by Chao (1996) suggest that cisplatin resistance could be 
attributed to the elevation of various enzymes involved in DNA excision repair, such 
as polymerase and thymidine triphosphate synthesis inhibitors and agents affecting 
topoisomerase II and DNA accessibility.  An important finding is that DNA repair is 
always increased in resistant cells, while drug uptake, efflux, GSH level or MT level 
may remain unchanged.  Since increased DNA repair occurs early and consistently 
 30 
during cisplatin selection, it appears to be activated first, and then the cell may induce 
additional mechanisms affecting GSH, MT, drug accumulation and efflux in order to 
achieve higher degrees of resistance (Chao, 1996 and Helm and States, 2009). 
 
Genomic instability [characterised as microsatellite instability (MIN)] is associated 
with loss of DNA mismatch repair (MMR) protein.  Several studies showed that loss 
of DNA MMR protein confers resistance to some interacting DNA chemotherapeutic 
drugs.  This was mainly reported for cisplatin (Picard et al. 2002).  It has been 
postulated that tumours that are defective in MMR become more resistant to cisplatin 
than their MMR-proficient counterparts (Rosell et al. 2003). 
 
1.4.4 Cisplatin analogues 
 
Although cisplatin has been used since 1978 it has many disadvantages and research 
is ongoing towards improved anticancer agents.  In order to understand the reasons for 
its very moderate performance it is necessary to investigate its chemical and structural 
properties.  Very recently an article appeared in Inorganic Chemistry which stated that 
the unstable tetraaqua Pt(II) complex consists of a distorted pentacoordinated 
structure in perchloric acid solution with four equidistant oxygen atoms of H2O in the 
xy plane and a longer distant oxygen atom on the z axis.  It was also stated that the 
cis-diamminediaquaplatinum(II)  ion is very similar.  This sheds some light on the 
reactivity of cisplatin.  It seems to suggest that the Pt(II), when surrounded by such 
small donors, is very “open” towards attack for formation of relatively low activation 
energies for ligand exchange (Galilehvand and Laffin, 2008).   
 
This provides useful information for the search for analogues.  Once a successful drug 
has been discovered for the treatment of a particular disease or condition, researchers 
will often try to improve on that drug by synthesizing and studying related 
compounds, referred to as analogues or second-generation drugs.  The reasons for 
manufacture of such analogues include (i) the analogues may be able to improve on 
the efficacy of the original drug, meaning that lower doses are able to produce the 
same beneficial effects; (ii) the toxicity profile of the analogues may be better than 
that of the original drug; hence, the analogues may have fewer toxic side effects than 
the original drug; (iii) the analogues may be used to treat cases that have become 
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resistant to the original drug and; (iv) if the original drug can only be administered 
intravenously, the analogues may be able to be taken orally. After the efficacy and 
toxicity profiles of second-generation analogues are obtained, more analogues can be 
synthesized and studied; these analogues are called third-generation drugs.  Many 
second-generation analogues of cisplatin have been made; some have been found to 
produce the same therapeutic effects as cisplatin; but with lower required doses and 
reduced side effects.  The second generation platinum drugs, carboplatin, nedaplatin 
and oxaliplatin have all exchanged the Cl− leaving groups of cisplatin for kinetically 
less labile chelating dicarboxylate or glycolate ligands.  As a result, patients treated 
with these compounds suffer from less severe dose-limiting side effects (Zutphen et 
al. 2006). 
 
Carboplatin [diammine{1,1-cyclobutane-dicarboxylato}platinum{II} or CBDCA for 
short has proven to be the most useful of the cisplatin analogues, and was approved by 
the FDA for the treatment of ovarian cancers in 1989.  Carboplatin and cisplatin have 
been shown to form an identical type of adduct with DNA and have similar activities 
against ovarian and lung tumours.  However, carboplatin is less toxic to the peripheral 
nervous system and the kidneys.  The reduced toxicity of carboplatin compared to 
cisplatin is thought to be due to the structure of carboplatin (Figure 1.3B).  The 
presence of the bidentate dicarboxylate ligand (Figure 1.10) in carboplatin slows 
down the degradation of carboplatin into potentially damaging derivatives (Atsushi et 
al. 1994; Go and Adjei, 1999 and Katsuyuki and Keitara, 2007).  
 
Figure 1.10: A carboxylate and dicarboxylate group.  The dicarboxylate group is a bidentate 
ligand; hence it can bind a metal ion in two places 
(http://science.kennesaw.edu/~mhermes/cisplat/cisplat13.htm). 
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At 37°C the retention half-life of carboplatin in blood plasma is 30 hours, whereas 
that for cisplatin is only 1.5-3.6 hours.  In addition to the lower toxicity of carboplatin, 
it has been shown to work in some cases when cisplatin has failed.  The decreased 
toxicity of carboplatin and the activity of carboplatin against cisplatin-resistant 
tumours have led to greater use of carboplatin (Atsushi et al. 1994; Go and Adjei, 
1999 and Katsuyuki and Keitara, 2007).  Unfortunately tumours resistant to 
carboplatin are becoming more common, and the cause of drug resistance is unclear. 
 
The third most widely available drug related to cisplatin is oxaliplatin.  The dose-
limiting factor is sensory neuropathy.  Oxaliplatin is generally less toxic, with reduced 
myelosuppression, nephrotoxicity and ototoxicity; however, nausea and vomiting 
remain acute, but respond well to anti-emetics.  The activity of oxaliplatin has been 
shown to have a more powerful pharmacological effect than cisplatin, which is due to 
its different mechanism of action.  Studies indicate it attaches onto proteins, which are 
vital for DNA transcription, thus preventing cell division and causing eventual cell 
death (Ibrahim et al. 2004 and Helberg et al. 2009). Oxaliplatin is active in the 
treatment of colorectal cancers, while cisplatin and carboplatin are inactive (Hector et 
al. 2001).  Oxaliplatin disrupts DNA replication and transcription by the formation of 
intrastrand DNA adducts, but the downstream molecular events underlying the 
cytotoxic effects of this chemotherapeutic agent have not been well characterised.  
Arango et al. (2004) showed that exposure of proliferating colorectal cancer cells to 
oxaliplatin induces a G2/M phase arrest in the DNA cell cycle and a molecular 
cascade of events consistent with an intrinsic mechanism of apoptosis.  They also 
discovered that the apoptotic cascade initiated by oxaliplatin is characterised by 
translocation of Bax to the mitochondria and cytochrome c release into the cytosol.  
Oxaliplatin treatment resulted in caspase 3 activation and oxaliplatin-induced 
apoptosis was counteracted by inhibition of caspase activity, but was independent of 
Fas/FasL association (Arango et al. 2004). 
 
In addition to second-generation cisplatin analogues, several third-generation drugs 
have been synthesized and tested.  One broad class of these drugs, the amine/ammine 
platinum (IV) dicarboxylates (Figure 1.11), can be taken orally, which is a noteworthy 
advance over cisplatin, which must be administered intravenously.  These complexes 
are stable enough to survive passage down the digestive tract.  They are then 
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transported across the gastrointestinal mucosa into the bloodstream. After absorption 
into the bloodstream, these compounds are metabolised to form four-coordinate, 
platinum(II) cisplatin analogues.  These new four-coordinate complexes are assumed 
to be the active forms of the drug (Atsushi et al. 1994; Go and Adjei, 1997 and 
Katsuyuki and Keitara, 2007).  It has been found that bulky ligands destabilize the 
six-coordinate platinum (IV) state, which results in a faster rate of reduction to the 
four-coordinate platinum (II) state, and that a compound with a faster reduction time 
exhibits the highest cytotoxicity (Choi et al. 1998). 
 
 
Figure 1.11: The general structure of amine/ ammine platinum (IV) dicarboxylates.  Many 
different R and R’ groups were tried; two examples for each are shown here 
(http://science.kennesaw.edu/~mhermes/cisplat/cisplat13.htm). 
 
During the last 30 years, thousands of cisplatin analogues have been prepared by 
varying the nature of the leaving groups and the carrier ligands.  However, all 
cisplatin analogues in general form similar adducts with DNA that often translate into 
a similar spectrum of activity.  Hence, recently attention has been given to platinum 
compounds with structures distinctly different from that of cisplatin, with the idea that 
their different nature of interaction with DNA would translate into different spectrums 
of activity and toxicity profile.  One such class of compounds is the polynuclear 
platinum complexes that contain two or more platinum units linked together by di-
amino-alkane chains.  An important example is BBR3464 that consists of three trans-
platinum units joined together by two 1,6-di-amino-hexane chains.  BBR3464 has 
been found to evade the inherent or acquired cisplatin-resistance in vitro and in vivo in 
a panel of human adult tumour models.  BBR3464 was in phase II stage of clinical 
trial before it was stopped due to significant toxicity namely neutropenias, diarrhoea 
and nausea (Huq et al. 2004).  These multinuclear complexes exhibit different levels 
of cellular uptake and form a higher proportion of interstrand cross-links than 
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cisplatin or carboplatin, and it is thought that these complexes derive their improved 
activity primarily from the different adducts that they form with DNA (Wheate et al. 
2001).  It has therapeutic doses approximately one-tenth that of cisplatin, activity in a 
broad spectrum of human tumours and is active against cisplatin resistant cell lines.  
Hence, BBR3464 represents the first genuinely new platinum-based structure to enter 
clinical trials in 30 years (Roberts et al. 1999). 
 
Among the signal transducer and activator of transcription (STAT) proteins, Stat3 
activity is frequently up-regulated in many human tumours.  Thus, targeting Stat3 as 
novel cancer therapeutics has become an important research topic.  Turkson et al. 
(2004) reports that certain platinum-containing compounds disrupt Stat3 signalling 
and suppress its biological functions.  They showed that the novel platinum (IV) 
compound, CPA7 (Pt(NH3)2Cl3(NO2)), blocks Stat3 activity in vitro at low 
micromolar concentrations.  In malignant cells that harbor constitutively activated 
Stat3, CPA7 inhibits cell growth and induces apoptosis in a manner that reflects the 
decrease of persistent Stat3 activity.  Cells that do not contain persistent Stat3 activity 
are marginally affected or are not affected by these compounds at all.  Thus, the 
modulation of oncogenic signal transduction pathways, such as Stat3, may be one of 
the key molecular mechanisms for the antitumour effects of platinum (IV)–containing 
complexes.  CPA7 interferes with Stat3 and disrupts its ability to bind to DNA in 
vitro. (Turkson et al. 2004) 
 
1.5 MANGIFERIN 
 
As stated earlier, combination therapy of Pt(II) anticancer agents with other 
molecules, having similar properties, was shown to have synergistic effects.  Phenolic 
antioxidants have been found to exhibit anti-inflammatory, anticarcinogenic, and 
antidiabetic activities in animals.  Humans consume these antioxidants from dietary 
sources, either as natural components or as synthetic food additives.  This broad 
spectrum of the function of phenolic antioxidants suggests that there may be multiple 
targets through which they interfere with various cellular functions and protect against 
pathological lesions such as cancer and inflammatory diseases.  There is an increasing 
interest in the therapeutic use of antioxidants to prevent tissue damage induced by 
overproduction of reactive oxygen intermediates (ROI), by reducing free radical 
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formation or by scavenging or promoting the breakdown of these species.  Recently, 
the polyphenol mangiferin, a C-glucosylxanthone, specifically 1,3,6,7-
hydroxyxanthone-C2-β-D-glucoside (figure 1.12), has attracted considerable interest 
in view of its numerous pharmacological activities, which includes antitumour, 
antiviral, antidiabetic, anti bone resorption, and antioxidant activity (Sarkar et al. 
2004).  Mangiferin is a major component of Honeybush tea, prepared from Cyclopia 
spp. (Marnewick et al. 2000).   
 
 
 
Figure 1.12 The structure of mangiferin (1,3,6,7-hydroxyxanthone-C2-β-D-glucoside) (Jung et 
al., 2009). 
 
Honeybush (Cyclopia spp.) is indigenous to the cape of South Africa and is used to 
make a beverage and a medicinal tea.  It has become internationally known as a 
substitute for ordinary tea (Camellia sinensis) and with the dramatic growth in the use 
of honeybush during the past years, export of honeybush tea products is now a major 
industry, following up on the success of rooibos.  The honeybush plant is easily 
recognized by its trifoliate leaves, single-flowered inflorescences, and sweetly 
scented, bright yellow flowers.  The most sought-after components for the tea are the 
leaves and flowers but the stems are also included.  Honeybush tea is made as a 
simple herbal infusion and one of its recognized benefits as a tea substitute is its lack 
of caffeine, which makes it particularly suited for nighttime consumption and for 
those who experience nervousness and want to avoid ordinary tea.  Hence, it has a 
reputation as a calming beverage, though it may not have any specific sedative 
properties.  It also has low tannin content.  The tea can be consumed daily, or rotated 
with other teas, such as rooibos and ordinary tea (Marnewick et al. 2004).  
As carcinogenic, inflammatory, and growth modulatory effects of many chemicals are 
mediated by NFĸB, it has been hypothesized by Sarkar et al. (2004) that the 
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suppression of the NFĸB activation pathway accounts for mangiferin activity.  They 
have shown that mangiferin inhibits NFĸB by preventing the activation of IKK 
followed by phosphorylation and degradation of its inhibitory subunit IĸBα.  They 
have demonstrated that mangiferin increases glutathione level and inhibits TNF-
activated ROI and proved that downregulation of NFĸB by mangiferin leads to 
potentiation of chemotherapeutic agent-mediated apoptosis. 
 
There is a growing interest in substances exhibiting antioxidant properties that are 
supplied to humans as food components or as specific preventive pharmaceuticals.  
The plant kingdom offers a broad range of natural antioxidants and phenolics have 
been shown to provide a defense against oxidative stress from oxidizing agents and 
free radicals. Many herbal infusions have antioxidative and pharmacological 
properties related to the presence of phenolic compounds (Osama et al. 2009). 
 
 
1.6 INTRODUCTION TO THE PRESENT STUDY 
 
Cancer is a universal problem, which affects many people.  Cisplatin showed great 
promise in the treatment of cancer, however, due to the numerous toxic side effects 
and the emergence of cisplatin resistant cell lines, drugs with less toxic side effects, 
improved cytotoxicity against cancer cells and activity against cisplatin resistant cell 
lines are urgently needed.  If mangiferin, a natural polyphenol found in Cyclopia spp., 
aids in the enhanced anticancer action of some novel platinum containing complexes, 
a new combination therapy against cancer can be proposed.  Furthermore, the use of 
traditional herbal medicines in these treatments might render it more acceptable to 
many South Africans.  Hence, the development and screening of novel anti-tumour 
drugs and the discovery of the effects that mangiferin might have on the anti-cancer 
action of these drugs is imperative.   
 
A programme for the development of novel platinum containing anticancer agents has 
been initiated at this university.  The expertise of both the chemistry and biochemistry 
departments has been used to develop novel platinum containing compounds.  As 
mentioned before, the Research Unit for Platinum Group Chemistry, plan, synthesize 
and characterise the chemical aspects and the Biochemistry Department evaluates the 
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anticancer action in terms of their efficacy in killing a number of types of cancer cells 
as well as their mode of anticancer action.  The latter study is essential to provide 
feedback, which enables a correlation of their anticancer properties with their 
structure and physical chemical characteristics.  
 
This thesis focuses mainly on the biochemical aspects of this project.  This study 
assessed novel platinum containing compounds for possible enhanced cytotoxicity 
against cancer cells.  In addition, the effects of mangiferin on the anticancer action of 
these compounds were also investigated.   
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CHAPTER 2 
A COMBINATION OF PLATINUM ANTICANCER DRUGS 
AND MANGIFERIN CAUSES INCREASED EFFICACY IN CANCER CELL 
LINES  
 
2.1 INTRODUCTION 
 
A programme for the development of novel platinum containing anticancer agents has 
been initiated at this university.  The expertise of both the chemistry and biochemistry 
departments has been used to develop novel platinum containing compounds.  
 
The Research Unit for Platinum Group Chemistry plan, synthesize and characterize 
the chemical aspects and the Biochemistry Department evaluates the anticancer action 
in terms of their efficacy in killing a number of types of cancer cells as well as their 
mode of anticancer action.  The latter study is essential to provide feedback, which 
enables a correlation of their anticancer properties with their structure and physical 
chemical characteristics.  
 
This thesis focuses mainly on the biochemical aspects of this project.  This study 
assessed novel platinum containing compounds for possible enhanced cytotoxicity 
against cancer cells.  The first order screening involved the testing of the anticancer 
efficacy of approximately 400 novel complexes (synthesized by the Research Unit for 
Platinum Group Chemistry), by performing the MTT assay on HeLa, HT29 and 
MCF7 cancer cells after they were treated with 100 and 10μM solutions of these 
complexes for 48 hours.  The results obtained were compared to that of cisplatin 
(positive control) and accordingly the most active of these complexes were chosen for 
further studies.  Of these novel complexes, approximately 2% showed activity similar 
or better than cisplatin; approximately 40% showed activity that was less than that of 
cisplatin and approximately 58% showed very slight or no activity.  Since these 
complexes were screened without any knowledge of their structures, no conclusions 
relevant to this study could be made from the screening results obtained and therefore 
these results were not included.  These chosen drugs were then tested for increased 
efficacy when applied in combination with 10µg/ml mangiferin.  Additionally, it was 
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verified whether some of these compounds were capable of inducing resistance in the 
cell lines tested and whether the combination with mangiferin would affect the degree 
of resistance induced.  The mechanism of action of these drugs, alone, and in 
combination with mangiferin was also studied.   
 
The complexes selected for this study were Pt(dach)C2O4, i.e. oxaliplatin (dach=trans-
R,R-1,2-diaminocyclohexane); 
Pt(hme)Cl2 (Bouwer, 2008) (hme=L-histidinemethylester) – abbreviated as (Yol25); 
Pt(ama)Cl2 (Bouwer, 2008) (ama=2-aminobenzylamine) – abbreviated as (Yol29.1); 
Pt(dach)(C2O4)NO2)Cl (Louw, 2008) – abbreviated as (Mar 4.1.4); 
and Pt(NH3)2Cl3(NO2) referred to as CPA7 (Anagnostopoulou et al. 2006)) 
The above complexes were all produced in high degree of purity (>98.5%) 
 
The objectives of this study were: (1) To screen novel platinum containing 
compounds against selected cancer cell lines and compare their activities to that of 
cisplatin; (2) To confirm whether mangiferin enhances the cytotoxicity of some of 
these compounds; (3) To determine the mode of anticancer action of these compounds 
and; (4) To determine the mode of anticancer action of these compounds when 
applied in combination with mangiferin; (5) To determine whether these compounds, 
with and without the addition of mangiferin, cause  the development of resistant 
cancer cell lines. 
 
2.2 MATERIALS AND METHODS 
 
2.2.1 Drugs.  Cisplatin, oxaliplatin, Yol 25, Yol 29.1, Mar 4.1.4 and CPA7 
(described above) were synthesized by the Research Unit for Platinum Group 
Chemistry at the Nelson Mandela Metropolitan University.  The drug solutions were 
prepared fresh on the day of use by dissolving the required concentration in 
RPMI1640 (Sigma) containing 10% foetal calf serum (Delta Bioproducts, South 
Africa) by vortexing (1 minute) followed by sonication (15 minutes).  One millilitre 
of these solutions was then sent for Inductively Coupled Plasma Mass Spectrometer 
(ICP-MS) analysis, where the exact concentration of platinum present in the solutions 
was determined and the ICP-MS value calculated.  This was necessary because of the 
low solubility of some of the compounds and allowed for more accurate comparison 
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of cytotoxicity of different compounds.  Mangiferin was purchased from Sigma and 
the required concentrations were also prepared fresh in RPMI1640 containing 10% 
foetal calf serum on the day of use.   
 
2.2.2 Cell Lines.  Three human cancer cell lines, HeLa (cervical cancer), HT29 
(colon cancer) and MCF7 (breast cancer) (Highveld Biological; Johannesburg), were 
maintained in 10 cm culture dishes (Nunc) at 37ºC in a humidified incubator 
containing 5% CO2 in RPMI1640 supplemented with 10% foetal calf serum.  The 
cells were found to be mycoplasma free via screening with the MycoProbeTM 
Mycoplasma Detection Kit (R&D Systems). 
 
2.2.3 Cytotoxicity and dose response curves.  Cytotoxicity screening of 
approximately 400 novel compounds and dose response curves for selected 
compounds were performed by using the MTT assay (Sigma).  The IC50 values were 
calculated using the GraphPad Prism4 software package.  The reduction of 
tetrazolium salts is widely accepted as a reliable way to examine cell proliferation.  
The yellow tetrazolium salt MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide) is reduced by metabolically active cells, in part by the 
action of dehydrogenase enzymes.  The resulting intracellular purple formazan can be 
solubilized and quantified by spectrophotometric means.  The MTT cell proliferation 
assay measures the cell proliferation rate and conversely, when metabolic events lead 
to apoptosis or necrosis, the reduction in cell viability.  The MTT reagent yields low 
background absorbance values in the absence of cells (Hagopian et al. 1999 and Huq 
et al. 2004).   
 
Cells (200µl per well) were seeded in flat-bottom 96 well culture plates (Nunc) at 30 
000 cells per milliliter and incubated overnight at 37ºC in a humidified incubator 
containing 5% CO2.  Cells were allowed to attach and recover for 24 hours before the 
platinum containing complexes were added to the wells at concentrations of 100 and 
10µM (for screening) or 100, 50, 25, 10, 5 and 1µM (for dose response curves), with 
and without the addition of 10µg/ml mangiferin, and incubated for 48 hours before the 
MTT assay was performed.  A stock solution of MTT was prepared in PBSA 
(5mg/ml) and further diluted to 0.5mg/ml with RPMI1640 containing 10% foetal calf 
serum.  The medium was removed from the wells and replaced by this MTT solution 
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(200µL aliquots) before the plates were incubated for another 3 hours.  After 
incubation the MTT solution was removed from the wells and replaced by 200µL 
DMSO before the plates were analyzed on a Labsystems Multiskan MS Plate Reader 
at 540nm.  
 
2.2.4 Active caspase 3 levels.  Caspases (cysteine aspartic acid-specific proteases) 
play a key initiator role in the intrinsic apoptotic pathway of mammalian cells.  
Caspase 3 is one of the key executioners of apoptosis.  It is either partially or totally 
responsible for the proteolytic cleavage of many key proteins.  Proteolytic processing 
of its inactive zymogen into activated p17 and p12 fragments causes its activation.  
Active caspase 3 levels were determined using the Cleaved Caspase 3 (Asp 175) 
Alexa Fluor® 488 Antibody (Beckman Coulter).  The anti-Cleaved Caspase-3 
(Asp175) Antibody detects endogenous levels of the large fragment of activated 
caspase 3, which results from cleavage adjacent to aspartic acid 175.  The antibody 
does not recognize full length caspase 3 or other cleaved caspases.  
 
Cells were seeded into 10cm cell culture dishes (Nunc) at 1.15x105 cells per ml and 
incubated in a 37ºC incubator supplemented with 5% CO2.  Cells were allowed to 
attach and recover for 24 hours before 10µM of the platinum containing complexes 
were added to cells, with and without the addition of 10µg/ml mangiferin, and 
incubated for 15 hours.  The assay was performed, as per kit instructions, and 
analyzed on a Beckman Coulter FC500 flow cytometer.  An appropriate isotypic 
control antibody was used to ensure that antibody binding was specific. 
 
2.2.5 LDH release.  Lactate dehydrogenase is a cytosolic enzyme that catalyses the 
transformation of pyruvate to lactate.  It is released from the cell upon loss of plasma 
membrane integrity or necrosis.  LDH release was determined using the CytoTox 96® 
Non-Radioactive Cytotoxicity Assay (Promega).  This kit quantitatively measures 
LDH in culture supernatants with a 30-minute coupled enzymatic assay, which results 
in the conversion of a tetrazolium salt (INT) into a red formazan product.  The amount 
of colour formed is proportional to the number of lysed cells.  The reaction is as 
follows: 
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                                                                                               LDH 
NAD+ + lactate  →  Pyruvate + NADH 
                                                                                   Diaphorase 
NADH + INT → NAD+ + formazan (red) 
 
Cells (200µl per well) were seeded in flat-bottom 96 well culture plates (Nunc) at 30 
000 cells per milliliter and incubated overnight at 37ºC in a humidified incubator 
containing 5% CO2.  Cells were allowed to attach and recover for 24 hours before 
they were incubated for 48 hours with 100µM of the platinum containing complexes, 
with and without the addition of 10µg/ml mangiferin.  The assay was performed as 
per kit instructions and the results analyzed on a Labsystems Multiskan MS Plate 
Reader at 492nm. 
 
2.2.6 Trypan blue assay.  Trypan blue stains non-viable cells a bright blue colour, 
since it is able to enter the “leaking” cell membranes of these cells and is not able to 
enter the intact membranes of viable cells.  The trypan blue assay was performed 
using a standard 0.4% trypan blue solution (Sigma) in phosphate buffered saline 
without calcium or magnesium.  Cells (1ml per well) were seeded in flat-bottom 24 
well culture plates (Nunc) at 500 000 cells per milliliter and incubated overnight at 
37ºC in a humidified incubator containing 5% CO2.  Cells were allowed to attach and 
recover for 24 hours before they were exposed to 10µM of the platinum containing 
complexes, with and without the addition of 10µg/ml mangiferin for 48 hours.  The 
cells were trypsinized and counted with a heamocytometer in a 1:1 dilution of cells in 
a 0.4% trypan blue solution and the percentage of non-viable cells was calculated. 
 
2.2.7 DNA cell cycle analysis.  Flow cytometry was once considered to be the sole 
domain of immunologists, but has now evolved into a broadly applicable assay 
platform due to technological advances in accessory equipment and reagents as well 
as in cytometer changes.  Due to a wide variety of dyes and assays, a flow cytometer 
can be used to gain multiplex information in a single assay or to perform a number of 
assays that will characterise compounds or elucidate end point mechanisms (Lem and 
Cappione, 2005).  Growth and proliferation in eukaryotic cells is characterized by 
distinct phases of development known as the cell cycle.  The sequence of cell cycle 
events can be identified as follows: Initiating from a quiescent or resting state (phase 
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G0), cell growth and preparation of chromosomes for replication takes place (phase 
G1).  The cycle continues with synthesis of DNA (S phase) and is followed by 
preparations for cell division (phase G2).  The cycle completes with mitosis (M 
phase) and is perpetuated with the newly divided cells.  Flow cytometry offers a rapid 
method for measuring the DNA content of cells and provides a convenient research 
tool to monitor cell cycle status and regulation. An exponentially growing population 
of cells will have a DNA content distribution containing an initial peak of G0/G1 
cells, a valley of S phase cells, and a second peak containing G2/M cells.  
Measurements can be performed and are based on the ability of nuclear dyes, such as 
DAPI and propidium iodide (PI), to bind selectively to DNA under appropriate 
staining conditions.  Cells stained with such dyes emit fluorescence in direct 
proportion to their DNA content (Enten and Monson, 2005).  Normal cell cycle events 
are governed by complex control mechanisms.  Cell cycle arrest most commonly 
occurs at the G1/S or G2/M boundaries.  When cells transform, these control 
mechanisms are altered and cell growth becomes uncontrolled.  Cell cycle analysis (or 
DNA cycle analysis) provides a useful tool in the search for new anticancer agents as 
it gives some insight into possible mechanisms of action of the drugs.  It is possible to 
visualise the stages affected, by comparing the area of the peaks (Figure 2.1).  A 
larger peak area indicates that the DNA cycle has been arrested or delayed at that 
particular stage, since the DNA could not move on to the next phase. 
 
DNA content 
Figure 2.1 A diagram indicating where the different DNA phases are depicted on a histogram 
obtained with the Beckman-Coulter FC500 flow cytometer.  (These results were 
obtained from HT29 control cells). 
 
Figure 2.1 shows where the different phases of the DNA cycle can be seen on the 
histograms that will be obtained from the Beckman-Coulter FC500 Flow Cytometer.  
DNA Phases 
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The Sub-G1 phase refers evidence for apoptosis.  Apoptotic cells can be seen to the 
left of the G0/G1 peak due to DNA fragmentation occurring during apoptosis, DNA is 
lost from the permeabilized cells thus rendering these cells with less DNA (Kwon et 
al. 2005).   
 
DNA cell cycle analysis was performed using the Coulter® DNA PrepTM Reagents Kit 
(Beckman Coulter).  This kit is used in the preparation of intact cells and isolated cell 
nuclei for the quantitative measurement of cellular DNA content via flow cytometry.  
This measurement is based upon the ability of PI to bind to double stranded nucleic 
acids under appropriate staining conditions.  PI binds to DNA by intercalating 
between the bases with little or no sequence preference; however, it also binds to 
RNA, necessitating treatment with nucleases to distinguish between RNA and DNA 
staining.  PI cannot enter intact membranes and are generally excluded from viable 
cells, therefore a premeabilisation reagent (in this case sodium azide) is used to allow 
dye penetration into the nucleus during cell cycle analysis.  DNA stained in this 
manner will emit fluorescence in direct proportion to their DNA content.  The flow 
cytometer measures the fluorescence from each stained cell as it passes through the 
laser beam.  Flow cytometric analysis provides quantitative data and the ability to 
measure large numbers of cells rapidly.   
 
Cells were seeded into 10cm cell culture dishes (Nunc) at 1.15x105 cells per ml and 
incubated in a 37ºC incubator supplemented with 5% CO2.  Cells were allowed to 
attach and recover for 24 hours before they were incubated for 48 hours with 10µM of 
the platinum containing complexes, with and without the addition of 10µg/ml 
mangiferin.  The assay was performed as per kit instructions and the results analyzed 
on a Beckman Coulter FC500 flow cytometer. 
 
2.2.8 DNA fragmentation assay.  DNA fragmentation assays were performed 
using the Apo-BRDUtm kit (Phoenix Flow Systems).  This kit is a two colour TUNEL 
(Terminal deoxynucleotide transferase dUTP Nick End Labelling assay) useful for 
labeling DNA breaks and total cellular DNA to detect apoptotic cells.  DNA in 
apoptotic cells is broken up by cellular nucleases, whereas DNA in non-apoptotic 
cells remains largely intact.  The DNA fragments cause a multitude of 3'-hydroxyl 
ends in the DNA.  This kit utilizes this feature by labeling the 3'-hydroxyl ends with 
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bromolated deoxyuridine triphosphate nucleotides (Br-dUTP).  The enzyme terminal 
deoxynucleotidyl transferase (TdT) catalyzes a template independent addition of the 
3'-hydroxyl ends of double or single stranded DNA.  Non-apoptotic cells do not 
incorporate such a high amount of Br-dUTP, since they lack these 3-hydroxyl ends, 
and the Br-dUTP sites are identified by a fluorescein labeled antiBrdU monoclonal 
antibody.   
 
HT29 cells (5mL aliquots) were seeded into 50ml non-adherent cell culture flasks 
(Nunc) at a density of 100 000 cells/mL and were incubated for 48 hours with 10µM 
of the platinum containing complexes, with and without the addition of 10µg/ml 
mangiferin, before the assay was performed as per kit instructions and the results 
analyzed on a Beckman Coulter FC500 flow cytometer. 
 
2.2.9 Mitochondrial transmembrane potential assay.  Mitochondria produce ATP 
through oxidative phosphorylation, which involves a series of redox reactions that 
transfer electrons through multiple protein complexes in the inner mitochondrial 
membrane.  Protons are then pumped out of the mitochondrial matrix, generating the 
mitochondrial membrane potential (ΔΨm), which is not only harnessed to generate 
ATP, but is also responsible for mitochondrial Ca2+ uptake, metabolite and protein 
transport, production of reactive oxygen species, and has also been related to the 
process of apoptosis.  Hence, the health and bioenergetic function of the mitochondria 
depend on its membrane potential.  Preservation of the ΔΨm is essential during normal 
conditions, and especially, during conditions of stress and disease.  Depolarization of 
the membrane results in a reduction of ATP production and is also thought to 
precipitate the release of pro-apoptotic factors in some cell systems.  Thus, there are 
good reasons to search for therapeutic agents that decrease ΔΨm as possible pro-
apoptotic drugs, for example, in the case of cancer (Wong and Cortopassi, 2002).   
 
Mitochondrial transmembrane potential studies were performed using the Guava® 
EasyCyteTM MitoPotentialTM Kit (Guava Technologies).   This kit is a mix and read 
multiparametric assay to measure mitochondrial membrane potential and apoptosis.  
JC-1, a cationic dye that fluoresces either green or orange depending upon 
mitochondrial membrane potential, is used to evaluate the mitochondrial membrane 
potential changes.  A second dye, 7-Aminoactinomycin (7-AAD) is used to measure 
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apoptosis.  Using both these dyes simultaneously will measure both the mitochondrial 
membrane potential changes and apoptosis.  Since apoptosis has already been 
measured previously, only JC-1 was used to stain the cells during this experiment.  
Healthy cells stained with JC-1 will fluoresce mostly orange as JC-aggregrates are 
formed in the mitochondria due to increases in the dye concentration.  As cells 
become apoptotic, holes form in the mitochondrial membranes, which allow the dye 
to leak into the cytoplasm where the dye exists as monomers.  This will result in the 
fluorescence of the dye to shift from mostly orange (FL2) to mostly green (FL1).  
HT29 cells were seeded into 50ml non-adherent cell culture flasks (Nunc) and were 
incubated for 48 hours with 10µM of the platinum containing complexes, with and 
without the addition of 10µg/ml mangiferin, before the assay was performed as per kit 
instructions (excluding the addition of 7-AAD) and the results analyzed on a 
Beckman Coulter FC500 flow cytometer. 
 
2.2.10 Induction of drug resistance.  This section of the work was done in an effort 
to determine whether the chosen compounds induce resistance in the cell lines (a big 
draw-back of existing anticancer drugs, such as cisplatin) as well as the effect 
mangiferin will have on this induction of resistance.  These resistant cells were 
developed according to the method of Godwin et al. (1992).  HeLa, HT29 and MCF7 
cancer cells were exposed intermittently and incrementally to the complexes, with and 
without the addition of 10µg/ml mangiferin.  Table 2.1 illustrates the conditions for 
inducing resistance in these cells.  The cells were maintained as described in section 
2.2.2 and subcultured via trypsinization as soon as 80% confluency was reached 
(monitored microscopically).  After trypsinization cells were maintained in 
RPMI1640 containing 10% foetal calf serum for at least one more subculture, 
depending on the general appearance of these cells, microscopically, before the next 
exposure to the treatments.  If the cells did not grow optimally during this period or 
looked unhealthy, an additional subculture and growing period without the addition of 
the treatments were allowed in an attempt to avoid the untimely demise of these cells.  
In the event of such demise, the experiment had to be repeated from the beginning on 
normal control cells, as shown in table 2.1.  This procedure typically extended over a 
period of 12 to 16 weeks.  The degree of resistance was determined by performing 
dose response curves on these cells as described in section 2.2.3. 
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Table 2.1: The conditions for inducing cisplatin resistance in cancer cell lines 
[Cisplatin] (µM) Time exposed (hours) 
10 0.5 
10 1.0 
10 1.5 
100 0.5 
100 1.0 
100 1.5 
100 1.0 
100 1.0 
 
2.2.11 NFκB Assay.  Members of the Rel/NFĸB family of transcription factors form 
one of the first lines of defense against infectious diseases and cellular stress.  They 
initiate a highly coordinated response in multiple cell types that efficiently counteracts 
the threat to the health of the organism.  Activation of NFĸB occurs in response to a 
wide variety of stimuli, i.e. cytokines, growth factors, physiological, physical and 
oxidative stress and certain pharmaceutical drugs and chemicals.  These stimuli 
generally target the protein IĸB, to which the two major subunits of NFĸB, p50 and 
p65, are bound to form inactive NFĸB/IĸB complexes.  Phosphorylation and 
ubiquitination of IĸB protein releases NFĸB, allowing it to translocate into the nucleus 
as the activated form. The Phospho-NFκB p65 (Ser536) (93H1) Rabbit mAb (Alexa 
Fluor®488 Conjugate) (Cell Signalling Technology) was used to study the effect of 
drug resistance, with and without the addition of 10µg/ml mangiferin, on the 
expression of NFκB.  This antibody recognises Phospho-NFĸB p65 (Ser536) from 
human, mouse and rat only when phosphorylated at serine 536.  It does not cross-react 
with the p50 subunit or other related proteins.  HT29 cells (5 mL aliquots) were 
seeded into 50ml non-adherent cell culture flasks (Nunc) at a density of 100 000 
cells/mL and were incubated for 48 hours with 10µM of the respective test 
compounds, with and without the addition of 10µg/ml mangiferin, before the assay 
was performed as per kit instructions and the results analyzed on a Beckman Coulter 
FC500 flow cytometer with a minimum of 10 000 events being recorded.  Rabbit IgG 
isotype control was used.   
 
2.2.12 Statistical analysis. Statistical analysis was performed via the Student’s t-
test.  Certain experiments (trypan blue assay and caspase 3 assay) were performed in 
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duplicate and therefore the average deviation of the values is depicted on the graphs.  
For flow cytometric analysis a minimum of 10 000 gated events were recorded.  IC50 
values were determined from dose-response curves using the GraphPad Prism4 
software package 
 
2.3 RESULTS 
 
2.3.1 Cell viability 
 
From the approximately 400 novel compounds that were screened for toxicity at 10 
and 100μM against HeLa, HT29 and MCF7 cells (results not shown), three were 
selected for further studies together with oxaliplatin and CPA7 as positive controls.  
The molecular formulae for these compounds were given in the introduction and for 
simplicity they will be referred to as Yol 25, Yol 29.1 and Mar 4.1.4.   
 
Dose response curves were obtained for the selected platinum compounds against 
HeLa, HT29 and MCF7 cells after a 48 hour exposure.  IC50 values were calculated 
from these curves.  From table 2.2 it can be seen that the IC50 values for Mar 4.1.4 
were lower than those of the positive controls against all three cell lines.  The other 
two selected compounds were not as effective in killing the cancer cells as Mar 4.1.4 
but they seemed to be more selective for the breast (MCF7) and cervical (HeLa) 
cancer cells.  The results in table 2.2 further indicate that mangiferin enhances the 
anticancer activity of the tested platinum containing anticancer drugs, as lower IC50 
values were obtained in combination with mangiferin in all samples except for 
oxaliplatin in MCF7 cells.  The approximate concentrations of oxaliplatin and 
cisplatin in the blood of an average (70kg) male after treatment are 52 and 97μM 
respectively.  Therefore, the decrease in the IC50 values caused by combination 
treatment may have a very significant effect in a patient.  It may also allow that a 
lower concentration of these drugs be administered, thus potentially decreasing the 
toxic side effects.     
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Table 2.2: The IC50 values obtained for the platinum drugs with and without the addition 
mangiferin. 
Compound Mangiferin added Cell line 
 10μg/ml HeLa HT29 MCF7 
Cisplatin No 10.66 8.15 14.26 
 Yes 8.28 (1.3) 5.61 (1.5) 11.48 (1.2) 
Oxaliplatin No 11.92 12.30 6.21 
 Yes 6.86 (1.7) 3.63 (3.4) 8.31 (0.75) 
Yol 25 No 8.70 21.11 6.79 
 Yes 5.89 (1.5) 12.53 (1.7) 4.96 (1.4) 
Yol 29.1 No 9.26 12.66 8.31 
 Yes 5.95 (1.6) 9.20 (1.4) 6.98 (1.2) 
CPA7 No 5.14 9.81 9.29 
 Yes 2.93 (1.8) 6.89 (1.4) 3.59 (2.6) 
Mar 4.1.4 No 4.81 3.07 5.86 
 Yes 2.53 (1.9) 1.94 (1.6) 1.89 (3.1) 
Brackets: Fold decrease in IC50 value compared to that of the same compound in the absence of mangiferin. 
    
During apoptosis, the plasma membrane remains intact to prevent “leakage” of 
cellular content into the surrounding tissue.  This prevents inflammation commonly 
associated with necrosis and is therefore the preferred method of cell death induced by 
chemotherapy.  By measuring trypan blue uptake or LDH release, one can obtain an 
indication of membrane integrity and therefore the type of cell death.  The trypan blue 
assay (table 2.3), showed a general decrease in the percentage of non-viable cells 
when treated with mangiferin.  Yol 29.1 and CPA7 were the exceptions and showed 
slight increases in the percentage of non-viable cells in MCF7 and HT29 cells.   
 
The trypan blue results correlated to most of the LDH assay results (figure 2.2), which 
showed a general decrease in the LDH release in combination with mangiferin.  These 
results might indicate that mangiferin favours cell death as a result of apoptosis, rather 
than necrosis.  Yol 25 was the only sample to show a significant increase in the 
amount of LDH release in the presence of mangiferin (this occurred in HeLa cells).  
Interestingly, both Yol 29.1 and CPA7 showed a significant decrease in the amount of 
LDH release in the presence of mangiferin in the cell lines in which an increase in 
viable cells were seen from the trypan blue assay (MCF7 and HT29 cells 
respectively).  Yol 25 also showed a significant decrease in LDH release by MCF7 
cells in the presence of mangiferin.  The fact that contradictory results were obtained 
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between the trypan blue and LDH assays for some compounds might also be 
attributed to the incubation times.  Some of these compounds are bound to act faster 
or slower than others.  The phenomenon of secondary necrosis, seen in in vitro studies 
but not in vivo, may also play a role here.  Interestingly, mangiferin, when applied 
alone, caused an increase in the percentage of LDH released.  Further studies were 
required to investigate the effect of mangiferin in the mode of cell death induced by 
the platinum compounds. 
 
Table 2.3: The percentage of non-viable cells (according to the trypan blue assay) with and 
without the addition of 10µg/ml mangiferin. 
Treatment 
(10μM) 
Mangiferin 
added (10μg/ml) 
HeLa HT29 MCF7 
Oxaliplatin No 80.7±1.1 55.6±8.3 54.2±4.2 
 Yes 45.7±2.6 (1.8) 42.6±3.4 (1.3) 33.5±5.7 (1.6) 
Yol 25 No 63.7±4.5 36.1±11.3 68.8±10.4 
 Yes 51.5±1.9 (1.2) 29.0±3.0 (1.2) 56.6±8.7 (1.2) 
Yol 29.1 No 81.6±0.3 57.1±9.8 47.9±6.3 
 Yes 65.7±3.1 (1.2) 72.3±7.4 (0.8) 65.8±0.5 (0.7) 
CPA7 No 91.4±0.5  80.9±1.0 80.0±5.0 
 Yes 83.1±0.1 (1.1) 85.4±1.1 (0.9) 84.3±0.1 (0.9) 
Mar 4.1.4 No 80.7±1.1 68.7±1.3 62.1±7.9 
 Yes 63.8±5.2 (1.3) 62.6±5.9 (1.1) 68.2±13.3 (0.9) 
Values represent mean ± average deviation, n=2; Brackets = fold decrease due to addition of mangiferin 
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Figure 2.2: The percentage LDH released with and without the addition of 10µg/ml mangiferin 
(values represent mean ± SEM; n = 8). (A) HeLa; (B) HT29; and (C) MCF7 cell line. 
* p≤0.05 ; #   p<0.01 as compared to corresponding treatment without mangiferin. 
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2.3.2 Cell cycle analysis 
 
The results obtained from the DNA cell cycle analysis of HT29 cells (figure 2.3A) 
indicates that mangiferin alone had no effect on the cell cycle of HT29 cells, but 
increased the amount of cells in the sub-G1 phase (apoptotic cells) from 2.6% to 
6.2%.  In the absence of mangiferin, oxaliplatin did not have any pronounced effect 
except for an increase in the sub-G1 peak to 6.4%.  Yol 25 and Yol 29.1 caused a 
slight increase in the G1/G0 peak, whereas CPA7 and Mar 4.1.4 both caused an 
accumulation of the cells in S phase and an increase in the sub-G1 peak.  CPA7 
clearly had the most pronounced effect on the cell cycle. 
 
It was found that mangiferin causes an earlier, enhanced delay in the S-phase in 
combination with oxaliplatin and Yol 25 and a later, enhanced delay in the S-phase in 
combination with CPA7.  It seems that Yol 29.1 and Mar 4.1.4 act similarly to CPA7, 
but a late S or early G2/M phase delay occur, as opposed to a strictly S phase delay 
seen in CPA7.  The percentage apoptosis (cells in the sub-G1 peak) was also 
increased in combination with mangiferin.  Cell cycle analysis was also performed on 
MCF7 and HeLa cells (Figure 2.3B and 2.3C respectively)   
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Figure 2.3A: DNA cell cycle analysis with and without addition of 10µg/ml mangiferin on HT29 
cells.  Regions indicate cell cycle phases: C = Sub-G1; D = G0/G1; E = S and F = 
G2/M phase.   
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Figure 2.3B: DNA cell cycle analysis with and without addition of 10µg/ml mangiferin on MCF7 
cells.  Regions indicate cell cycle phases: C = Sub-G1; D = G0/G1; E = S and F = 
G2/M phase.   
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Figure 2.3C: DNA cell cycle analysis with and without addition of 10µg/ml mangiferin on HeLa 
cells.  Regions indicate cell cycle phases: C = Sub-G1; D = G0/G1; E = S and F = 
G2/M phase.   
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Figure 2.3B shows that mangiferin alone causes a G0/G1 or very early S phase delay 
as well as increased apoptotic cells (sub-G1 phase) in MCF7 cells.  Oxaliplatin and 
Mar 4.1.4 showed a late S/ early G2/M phase delay as well as increased apoptosis for 
oxaliplatin, from 2.9% to 15.1%.  Yol 25 and CPA7 showed an S-phase delay with 
increased cells in the sub-G1 phase and Yol 29.1 showed only a slight increase in the 
sub-G1 phase with no other effects.   
 
In the presence of mangiferin, oxaliplatin, Yol 25, Yol 29.1 and Mar 4.1.4 showed an 
earlier, enhanced S-phase/ early G0/G1 phase delay, in MCF7 cells, with increased 
apoptosis for Yol 25, Yol 29.1 and Mar 4.1.4 (Figure 2.3B).  Oxaliplatin showed a 
decrease in cells in the sub-G1 phase.  CPA7 showed an increase in the sub-G1 phase, 
but the effect on the cell cycle cannot be differentiated because of the already 
pronounced S phase arrest seen even in the absence of mangiferin.   
 
Figure 2.3C shows that mangiferin alone caused a delay in the G2/M phase in HeLa 
cells.  There was no effect on the cells in the sub-G1 phase.  Oxaliplatin and Yol 25 
caused an S/ early G2/M phase delay, Yol 29.1 delayed the cell cycle in the G2/M 
phase whereas CPA7 and Mar 4.1.4 caused an early S phase delay.  There was a small 
increase in the amount of cells in the sub-G1 phase for all of the complexes, with a 
more significant increase occurring in the cells treated with Mar 4.1.4.  In the 
presence of mangiferin, oxaliplatin, CPA7 and Yol 25 treated MCF7 cells showed an 
earlier, enhanced S-phase delay with an increase the amount of cells in the sub-G1 
phase.  Yol 29.1 showed an earlier, delay in the S-phase.  There was also an increase 
in the sub-G1 peak.  Mar 4.1.4 showed G2/M phase delay but this might even have 
been a later, enhanced S-phase delay as well as more cells in the sub-G1 phase.  
Unfortunately, it cannot be said with absolute certainty during which phase the cell 
cycle is affected, because of a certain amount of overlap between the peaks of 
different phases.  Therefore, the broader terms such as early S/ late G0/G1 phase etc. 
are being used.  It was attempted to analyze the data with the Multicycle software 
package, but since these complexes induced such dramatic effects on the DNA cell 
cycle, the data could not be analyzed accurately with this software.   
 
Since similar results were obtained in all the cell lines, and oxaliplatin is currently 
being used clinically to treat colon cancer, only the HT29 cell line was tested for 
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DNA fragmentation and mitochondrial transmembrane potential to verify this 
increased apoptosis.  The DNA fragmentation assay (figure 2.5) showed that all 
samples had more DNA fragmentation in the presence of mangiferin except for 
CPA7, and the mitochondrial transmembrane potential assay (figure 2.6) showed 
more depolarization in the presence of mangiferin in all samples except for oxaliplatin 
and Mar 4.1.4.  
 
2.3.3 Apoptosis induction 
 
Caspase 3 is an executioner caspase commonly used as an indicator of apoptosis 
induction.  A monoclonal antibody raised specifically against the activated enzyme 
was used in conjunction with flow cytometry to compare the levels of active caspase 3 
in control cells with that in cells treated with the selected compounds and/or 
mangiferin.  Histograms of events versus fluorescence intensity (active caspase 3) 
were used to obtain the percentages of cells that stained positive for active caspase 3 
(see Figure 2.4A as an example) and these values were plotted as bar graphs (Figure 
2.4B and C).  Non-specific binding of the antibody was corrected for by using an 
isotype control antibody. 
 
All the platinum compounds increased the levels of activated caspase 3 in HeLa and 
HT29 cells, except for oxaliplatin in HT29 cells.  The most pronounced effect was 
seen with Yol 25 (figure 2.4A and B).  A further increase in the percentage of 
activated caspase 3 (figure 2.4) in oxaliplatin treated HeLa and HT29 cells, as well as 
in CPA7 treated HeLa cells, indicates that mangiferin may also aid in the caspase 3 
activation of some of these compounds.  However, a decrease in the activated caspase 
3 when exposed to the compounds plus mangiferin could also be seen in some of 
these compounds, especially in the HT29 cell line.  In both HeLa and HT29 cells 
mangiferin caused an increase in the amount of caspase 3 when applied alone, but a 
more pronounced increase was seen in the HT29 cell line.  The MCF7 cell line does 
not express caspase 3 (Yang et al. 2001), therefore only HeLa and HT29 cell lines 
were tested for activated caspase 3 activities. 
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Figure 2.4: Caspase 3 activated by platinum compounds with and without addition of 10µg/ml 
mangiferin.  (A) Histogram overlay as an example of the results obtained in HeLa 
cells:  Black = Control; Red = Yol 25 and Blue = Yol 25 + mangiferin treated cells;  
(B) A summary of the results obtained in HeLa cells, expressed as percentage cells 
that stained positive for active caspase 3; and (C) A summary of the results obtained 
in HT29 cells, expressed as percentage cells that stained positive for active caspase 3.   
Values in (B) and (C) represent mean ± average deviation, n=2. 
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The DNA fragmentation assay (figure 2.5) showed that all the samples had more 
DNA fragmentation in the presence of mangiferin except for CPA7.  Interestingly 
CPA7, when applied alone, showed the most DNA fragmentation of all the 
compounds tested, with and without mangiferin.  Even after the reduction in DNA 
fragmentation occurred in combination with mangiferin, it still exhibited the highest 
percentage of DNA fragmentation except for Mar 4.1.4 in the presence of mangiferin.  
This might suggest that CPA7 causes apoptosis via mechanisms involving DNA 
fragmentation.  The most pronounced increase in DNA fragmentation in the presence 
of mangiferin also occurred in Mar 4.1.4 treated cells.   
 
The mitochondrial transmembrane potential assay (figure 2.6) showed more 
depolarization in the presence of mangiferin in all samples except for oxaliplatin and 
Mar 4.1.4.  Mangiferin alone, as well as Yol 25 in combination with mangiferin 
showed the most significant increases in depolarized cells.  
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Figure 2.5: DNA fragmentation induced by platinum compounds in HT29 cells with and without 
the addition of 10µg/ml mangiferin.  (A1)  A Histogram of Events vs cells stained 
with fluorescein labeled antiBrdU monoclonal antibody (FL1 log) for negative 
control cells and (A2) its corresponding density plot of fluorescein labeled antiBrdU 
monoclonal antibody bound cells (FL1 log) vs DNA area (FL3 lin).  (B1) A 
Histogram of Events vs cells stained with fluorescein labeled antiBrdU monoclonal 
antibody (FL1 log) for oxaliplatin treated cells and (B2) its corresponding density 
plot of fluorescein labeled antiBrdU monoclonal antibody bound cells (FL1 log) vs 
DNA area (FL3 lin). (C)  A summary of the mean fluorescence intensity (FL1) 
results obtained calculated as a percentage of control (Bars indicate values from 
single experiment; a repeat of this experiment showed similar trends).  
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Figure 2.6: Mitchondrial membrane potential measured with JC1in HT29 cells exposed to 
platinum compounds with and without the addition of 10µg/ml mangiferin.  (A)  A 
density plot of FL1 log vs FL2 log for negative control cells.  (B)  A density plot of 
FL1 log vs FL2 log for oxaliplatin treated cells.  (C)  A summary of the results 
obtained for the platinum compounds expressed as the ratio of depolarized (FL1) to 
polarized (FL2) membranes via the mean fluorescence intensity values obtained for 
each (values represent mean±standard deviation; n=3) 
* p<0.001 as compared to corresponding treatment without mangiferin;  # p<0.05 and 
& p<0.001 as compared to the control.  
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2.3.4 Drug resistance 
 
Cancer cells develop resistance to most chemotherapeutic drugs over time and the 
search is ongoing for one that does not have this disadvantage.  The three cell lines 
used in this study were exposed to the compounds under investigation over long 
periods to establish whether or not resistance would develop.  Mangiferin has 
previously been shown to increase GSH levels.  Since increased GSH levels have also 
been associated with cisplatin resistance in tumours, drug resistance was also induced 
in the presence of mangiferin (Dunfield and Guernsey, 2002; Sarkar et al. 2004 and 
Turchi, 2006).   After exposure to the compounds, IC50 values were determined as a 
measure of the cells’ sensitivity to each compound.  The levels of activated NFκB 
were used as a further measure of drug resistance. 
 
The IC50 values depicted in table 2.4 generally indicate that resistant cells had a 
higher IC50 value than normal cells and that the presence of 10µg/ml mangiferin 
lowered the IC50 value in both normal and resistant cells.  The HT29 cell line was 
most prone to become resistant against the drugs, whereas the MCF7 cell line was the 
least prone to become resistant.  The presence of mangiferin had the most promising 
results in terms of lowering the IC50s in Yol 25 and oxaliplatin treatment, especially 
in the resistant cells.  Yol 29.1 showed the least promising results.  Oxaliplatin 
showed the most resistance induced, of all the complexes tested, in the HeLa and the 
HT29 cell lines.  It also showed a reduction in the IC50 values when combination 
treatment was applied.  This is very promising, since oxaliplatin is currently used to 
treat colon cancer and resistance induction is a negative feature of this drug.  Yol 25 
exposure did not influence the IC50 values in HeLa and MCF7 cells, but did cause an 
increase in the HT29 cells.  Combination treatment caused a decrease in the IC50 
values for all cell lines.  Yol 29.1 exposure did not influence the IC50 values in MCF7 
cells with and without combination treatment, but did cause increased IC50s in the 
other cell lines.  However, combination treatment with mangiferin caused a further 
increase in the IC50s instead of the expected decrease. CPA7 exposure did not 
influence the IC50 values in HT29 cells and a decrease in the value was seen in 
resistant HeLa cells.  Combination treatment with CPA7 and mangiferin caused a 
decrease in the IC50 value in MCF7 cells, but an increase in both HeLa and HT29 
cells.  Mar 4.1.4 did not seem to induce resistance in HeLa and MCF7 cells, but 
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combination treatment with mangiferin caused a decrease in the IC50s, especially in 
the MCF7 cell line.  However, in the cells that were resistance induced in the presence 
of mangiferin, an increase in the IC50s was seen.   
 
Table 2.4: The IC50 values for the platinum drugs against normal* as well as resistant** cells, 
with and without the addition of 10µg/ml mangiferin.  
Compound Mangiferin 
added 
(10µg/ml) 
Normal 
HeLa 
Resistant 
HeLa 
Normal 
HT29 
Resistant 
HT29 
Normal 
MCF7 
Resistant 
MCF7 
Oxaliplatin No 3 12 6 12 8 6 
 Yes 4 7 3 4 5 8 
Yol 25 No 9 9 21 26 7 7 
 Yes 6 5 13 18 5 6 
Yol 29.1 No 3 6 5 11 5 5 
 Yes 4 9 7 13 11 11 
CPA 7 No 5 4 10 10 9 5 
 Yes 3 4 7 11 4 3 
Mar 4.1.4 No 5 5 3 6 6 6 
 Yes 3 5 2 6 2 8 
Bold = Increase in IC50 value as compared to normal cells 
Italics = Decrease in IC50 values in presence of mangiferin 
* Cells not previously exposed to any platinum compound 
** Cells exposed intermittently and incrementally over a long period of time to the respective platinum 
compound. 
 
The NFκB assay (Figure 2.7) indicates that resistant HT29 cells had a higher amount 
of activated NFκB than normal HT29 cells for all complexes except Mar 4.1.4.  This 
amount of activated NFκB was reduced when resistance was induced in the presence 
of mangiferin in oxaliplatin, CPA7 and Yol 29.1 resistant cells.  Therefore, 
mangiferin has been shown to reduce the amount of activated NFκB associated with 
resistant tumour cells and may prove beneficial in the prevention of resistance to 
platinum anticancer drugs in tumour cells.  Yol 25 and Mar 4.1.4 showed an increase 
in the NFκB levels when mangiferin is present.  However, the presence of mangiferin 
did decrease the IC50 values; quite significantly, in Yol 25 treated HT29 cells (table 
2.4).  This suggests an alternative mechanism of resistance induction for this complex 
in HT29 cells (possibly increased GSH or MT levels, enhancing detoxification).  Mar 
4.1.4 might also exhibit such an alternative mode of resistance induction, although the 
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degree of resistance induced by this drug was not as significant (according to the 
IC50s) as for Yol 25.  
  
Normal cells treated with mangiferin alone showed an unexpected, increased amount 
of NFκB activation.  This suggests that mangiferin in combination with platinum 
containing complexes might have a synergistic effect and does not act as an NFκB 
inhibitor/ anticancer agent on its own.  It has been shown previously that the 
development of anti-cancer drugs that can “switch” the function of NFκB from anti-
apoptotic to pro-apoptotic may prove to be beneficial in the fight against cancer and 
that tumour prevention may be achieved through inhibition of abnormally active 
NFκB (Perkins, 2000; Perkins, 2004). 
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Figure 2.7: (A) Histogram overlay of the results obtained for the NFκB assay (Events vs FL1) in HT29 
cells.  Black = Control; Red = oxaliplatin resistant and Blue = oxaliplatin + mangiferin 
resistant cells.  (B-G) Activated NFκB (expressed as mean fluorescence intensity) in untreated 
and resistance-induced HT29 cells.  Resistance was induced through intermittent, incremental 
exposure to the respective complex or complex + 10μg/ml mangiferin.  These cells were 
finally seeded into culture flasks and levels of activated NF-κB measured in cells that received 
no further treatment (basal) or 10μM of the respective complex for a further 48 hours. [(B) 
Oxaliplatin; (C) CPA7; (D) Yol 25; (E) Yol 29.1; (F) Mar 4.1.4.; (G) Mangiferin alone]  Bars 
indicate values from single experiment, a repeat of this experiment showed similar trends.
C D 
E 
 A 
B 
F G 
FL 1 (Alexa-Fluor 488) 
E
v
e
n
t
s 
 66 
2.4 DISCUSSION 
 
Cancer is a universal problem, which affects many people.  Cisplatin showed great 
promise in the treatment of cancer, however, due to the numerous toxic side effects 
and the emergence of cisplatin resistant cell lines, drugs with less toxic side effects, 
improved cytotoxicity against cancer cells and activity against cisplatin resistant cell 
lines are urgently needed.  In this study it was shown that mangiferin, a natural 
polyphenol found in Cyclopia spp., Canscora decussata (Bhattacharya et al. 1972) 
and Mangifera indica (Muruganandan et al. 2005) aids in the enhanced anticancer 
action of oxaliplatin, CPA7 and three novel platinum containing anticancer drugs.  
Hence a new combination therapy against cancer can be proposed.  Furthermore, 
Honeybush tea that is a rich source of antioxidants may be used in conjunction with 
chemotherapy to reduce the side-effects associated with it (although some controversy 
still exists around this) (Drisko et al. 2003a, Drisko et al. 2003b and Lawenda et al. 
2008).  The use of traditional herbal medicines in these treatments might also render it 
more acceptable to many South Africans.   
 
The discovery that mangiferin decreases the IC50 values (table 2.2) of the platinum 
drugs by up to 3.4 times is very promising.  Caspases (cysteine aspartic acid-specific 
proteases) play a key initiator role in the intrinsic apoptotic pathway of mammalian 
cells.  The fact that an increase in the caspase 3 activity (figure 2.4) is observed during 
combination treatment with oxaliplatin and mangiferin in both HeLa and HT29 cells 
indicates that the decreased IC50 values may be due to increased apoptosis.  The 
concentration of oxaliplatin in the bloodstream of a patient after treatment is 
approximately 52μM (85mg/m2 administered).  Therefore, a 3.4 times decrease in the 
IC50 may implicate a much higher activity in vivo.  It may also mean that a much 
lower dose can be applied, thereby lessening the toxic side-effects associated with the 
treatment at such high doses.   
 
Lactate dehydrogenase is a cytosolic enzyme that catalyses the transformation of 
pyruvate to lactate.  It is released from the cell upon loss of plasma membrane 
integrity or necrosis (Tang et al. 2004).  The results obtained in this study (figure 2.2) 
indicate that some of the platinum drugs cause less LDH release when administered in 
combination with mangiferin.  Taken together with the lower IC50 values in the 
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presence of mangiferin, it can be assumed that less necrosis occurs in the cells when 
mangiferin is present.  These results correlated to the results obtained from the trypan 
blue assay (table 2.3).  A decrease in the amount of non-viable cells was observed in 
this assay for most compounds when applied in combination with mangiferin.  Trypan 
blue stains dead/ necrotic cells with “leaky” cell membranes, hence a decrease in the 
percentage of non-viable cells from this assay indicates less necrosis has taken place.  
These results therefore show strong evidence that mangiferin favours apoptotic cell 
death instead of necrosis.  CPA7 and Mar 4.1.4 in combination with mangiferin 
showed an increase in the caspase 3 activity in HeLa cells, but not in HT29 cells, 
suggesting different modes of action in these two cell lines.  Alternatively, it may also 
implicate that CPA7 and Mar 4.1.4 act much faster than the other complexes and that 
a shorter incubation time would have shown the desired results for these two 
complexes.  Interestingly, both CPA7 and Mar 4.1.4 are Pt(IV) complexes, which 
may also play a role in this observation and the reaction times mentioned above.  The 
MCF7 cell line was not tested for caspase 3 activity since this cell line does not 
express functional caspase 3. 
 
The results obtained from the DNA cell cycle analysis (figure 2.3) clearly shows an S-
phase arrest occurs in both oxaliplatin and CPA7 treated cells.  Fujie et al (2005) also 
showed that oxaliplatin causes an S or G2M phase delay in the cell cycle of HT29 
cells. Although mangiferin alone did not induce cell cycle arrest, the presence of 
mangiferin in combination with oxaliplatin shows an earlier and greatly enhanced 
delay in the S-phase, while cells treated with CPA7 in combination with mangiferin 
showed a later, but greatly enhanced delay in the S-phase.  Yol 25 acts similarly to 
oxaliplatin, whereas Yol 29.1 and Mar 4.1.4 seem to act similar to CPA7, although, in 
the latter, the delay in the S phase is very late and can be classified as a late S, early 
G2/M phase delay.  It would only be possible to identify the exact nature of the cell 
cycle arrest by investigating the presence of specific cyclins and cyclin-dependent 
kinases (CDKs).  DNA replication in eukaryotic cells takes place during the S phase.  
The transition from G1 into S phase in mammalian cells is regulated by at least two 
CDKs, cyclin E/Cdk2 and cyclin A/Cdk2.  Cyclin E/Cdk2 activity appears in late G1, 
while cyclin A/Cdk2 activity appears at the onset of DNA synthesis.  Cyclin A is also 
required later for the S/G2 transition (Frouin et al. 2002).   
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The Sub-G1 phase refers evidence for apoptosis.  Apoptotic cells can be seen to the 
left of the G0/G1 peak due to DNA fragmentation occurring during apoptosis, DNA is 
lost from the permeabilised cells, thus rendering these cells with less DNA (Kwon et 
al. 2005).  The percentage of apoptotic cells were also increased in the cells subjected 
to a combination treatment.   This was verified by a DNA fragmentation assay (figure 
2.5) that showed an increase in the amount of DNA fragmentation in HT29 cells 
subjected to a combination treatment in contrast to cells treated with the platinum 
containing complexes alone.  CPA7 however showed a decrease in the amount of 
DNA fragmentation when cells were treated in combination with mangiferin.  This 
finding, combined with the decreased caspase 3 activity in combination treatment of 
CPA7 and mangiferin on HT29 cells, might indicate that mitochondrial induced 
paraptotic cell death occurs in these cells (Tang et al. 2004).  A process that would be 
a ‘continuum’ between apoptosis and necrosis is referred to as ‘parapoptosis’ (De 
Souza Pagnussat et al. 2007).  Features characteristic of necrotic and apoptotic cell 
death are not only occurring in the same tissues but simultaneously in the same cells. 
Parapoptosis (also known as necrapoptosis), is a process that begins with a common 
death signal or toxic stress but that culminates in either necrosis or apoptosis, 
depending on other modifying factors.  Cell death mediated by the mitochondrial 
pathway illustrates this idea.  When onset of the mitochondrial membrane 
depolarization is rapid and cellular ATP levels drop dramatically, then early cell lysis 
ensues.  If this progression is slower, or if other sources of ATP generation are 
available, then profound ATP depletion is avoided, allowing apoptotic signalling to 
proceed.  Later if ATP levels finally collapse, cell lysis supervenes in a pattern of 
secondary necrosis.  Pure apoptosis and pure necrosis represent extremes in the 
spectrum of necrapoptotic responses, but the more typical response of tissues and cells 
to injurious stresses and other death signals is a mixture of events associated with 
apoptotic and necrotic cell death (Lemasters, 1999). 
 
Mitochondria produce ATP through oxidative phosphorylation, which involves a 
series of redox reactions that transfer electrons through multiple protein complexes in 
the inner mitochondrial membrane.  Protons are then pumped out of the mitochondrial 
matrix, generating the mitochondrial membrane potential (ΔΨm), which is not only 
harnessed to generate ATP, but is also responsible for mitochondrial Ca2+ uptake, 
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metabolite and protein transport, production of reactive oxygen species, and has also 
been related to the process of apoptosis.  Hence, the health and bioenergetic function 
of the mitochondria depend on its membrane potential.  Preservation of the ΔΨm is 
essential during normal conditions and, especially, during conditions of stress and 
disease.  Depolarization of the membrane results in a reduction of ATP production 
and is also thought to precipitate the release of pro-apoptotic factors in some cell 
systems.  Thus, there are good reasons to search for therapeutic agents to decrease 
ΔΨm as possible pro-apoptotic drugs, for example, in the case of cancer (Wong and 
Cortopassi, 2002).  This assay was performed to verify whether some platinum 
containing complexes use other mechanisms of action in combination with 
mangiferin, causing apoptosis.  The results obtained (figure 2.6) shows that the 
amount of depolarization does not increase in cells treated with oxaliplatin or Mar 
4.1.4 in combination with mangiferin, but does in cells treated with Yol 25, Yol 29.1 
and CPA7 in combination with mangiferin.  This may, again, be indicative of 
mitochondrial induced parapoptotic cell death in CPA7 treated cells.   
 
NFκB is a transcription factor that exerts anti-apoptotic effects and is often activated 
in cancer cells in response to chemotherapeutic agents.  This promotes cancer therapy 
resistance in tumours (Baldwin, 2001).  The improper activation of NFκB in diseases 
such as tumourigenesis (Lee et al. 2008 and Paul et al. 2006) has been linked to TNFα 
and other members of its superfamily.  Through the activation of NFκB, TNFα 
induces the expression of various genes that can be involved in tissue invasion and 
metastasis.  In addition, activation of NFκB can suppress apoptosis, which is likely to 
enhance tumourigenesis.  Many natural compounds, including the phenolics, have 
been found to inhibit upstream signalling molecules that are involved in TNFα 
expression (Paul et al. 2006).  Leiro et al. (2004) illustrated that mangiferin modulates 
the expression of a large number of genes that are critical for the regulation of 
apoptosis and tumourigenesis, and raised the possibility that it may be of value in the 
treatment of cancer.  Platinum drugs continue to be major chemotherapy drugs for 
cancer treatment.  Nevertheless, acquired or intrinsic resistance to these compounds is 
common in human tumours.  One mechanism of resistance induction is the avoidance 
of cells entering the apoptotic pathway.  NFκB is important in the final response of 
cells to platinum drugs, and it has been shown that inhibition of NFκB sensitizes 
cancer cells to the effects of these drugs.  New approaches focusing on the inhibition 
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of NFκB could help to minimize or even eliminate resistance to platinum drugs.  In 
order to increase the benefit of current platinum-based drugs and to direct effort to 
obtain improved agents, it is of great importance to understand the molecular basis of 
acquired and intrinsic resistance. Focusing on the inhibition of this factor could help 
to reduce or even eliminate resistance to platinum drugs or to provide drugs with less 
toxic side effects (Lagunas and Melendez-Zajgla, 2008). 
 
The NFκB assay (Fig. 2.7 A - E) indicates that all the resistant HT29 cells had a 
higher basal level of activated NFκB than normal HT29 cells, except for Mar 4.1.4 
resistant HT29 cells.  This was also true for CPA7 despite the fact that there is no 
increase in IC50 after resistance induction.  This amount of activated NFκB was 
reduced to below that of normal control cells when resistance to oxaliplatin and CPA7 
(fig. 2.7 A and B) was induced in the presence of mangiferin, while Yol 29 (Fig. 2.7 
D) also lead to a decrease in the NFκB levels, although not to below that of the 
normal (basal) level.  Therefore, for these three complexes, mangiferin has been 
shown to reduce the amount of activated NFκB associated with resistant tumour cells 
and may prove beneficial in the prevention of resistance to these platinum anticancer 
drugs in tumour cells.  After an additional treatment of the oxaliplatin plus mangiferin 
resistant cells with oxaliplatin, there is a further decrease in the amount of NFκB 
activated (Fig. 2.7 A).  These results indicate that mangiferin in combination with 
oxaliplatin, CPA7 and Yol 29 acts as an NFκB inhibitor.  Mangiferin alone does not 
act as an NFκB inhibitor, therefore the synergistic action of mangiferin and these 
complexes are very important.  It has been shown previously that the development of 
anti-cancer drugs that can “switch” the function of NFκB from anti-apoptotic to pro-
apoptotic may prove to be beneficial in the fight against cancer and that tumour 
prevention may be achieved through inhibition of abnormally active NFκB (Perkins, 
2000; Perkins, 2004). 
 
An additional treatment of the CPA7 + mangiferin resistant HT29 cells (Fig. 2.7 B) 
resulted in an increase in the activated NFκB levels.  Yol 25 and Mar 4.1.4 showed 
opposite behaviour to the previously discussed complexes.  Both these complexes 
show increased NFκB levels when resistance was induced in the presence of 
mangiferin, however an additional treatment with the respective complexes resulted in 
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lowered activated NFκB levels.  These results indicate a different mode of action for 
these two complexes. 
 
Mabuchi et al. (2004) showed that combination therapy of cisplatin with an NFκB 
inhibitor would increase the therapeutic efficacy of cisplatin.  Our results indicate that 
mangiferin is an NFκB inhibitor (Fig. 2.7) when applied in combination with platinum 
anticancer drugs and that it increases the therapeutic efficacy of platinum anticancer 
drugs and decreases the amount of resistance induced by these complexes (Table 2.4).  
Furthermore, we have shown evidence that mangiferin may counteract the 
development of resistance to oxaliplatin, CPA7 and Yol29.1 in HT29 colon cancer 
cells by reducing the activation of NFκB (Fig. 2.7 A, B and D).   
 
Mangiferin inhibits NF-κB and increases the intracellular GSH levels (Sarkar et al. 
2004). It is known that high GSH levels reduce the anticancer action of platinum 
drugs via detoxification.  It also plays a role in the induction of resistance towards 
these compounds in cancer cells (Turchi, 2006).  However, although GSH depletion 
could be useful to increase the therapeutic efficacy of cancer treatment by anticancer 
drug combinations (Meurette et al. 2005), the fact that mangiferin increases GSH 
levels does not seem to influence the efficacy of these combination treatments and 
further study into this finding needs to be conducted. 
 
In order to determine whether these compounds alone or in combination with 
mangiferin might be potential novel anticancer therapies, a summary of the results 
obtained for each novel compound follows.  Since oxaliplatin and CPA7 are used as 
references in this study, their typical effects on the three cancer cell lines will firstly 
be summarised. 
 
Oxaliplatin (Pt(dach)C2O4) exhibited the highest fold decrease (3.4x) of IC50 in the 
HT29 cells treated with oxaliplatin in combination with mangiferin.  This is very 
significant, since oxaliplatin is clinically used to treat colon cancer (Martin et al. 
2000).  There was a 1.7 fold decrease in the IC50 values in the HeLa cell line and a 
slight increase in the IC50 values was observed in the MCF7 cell line (0.75 fold 
decrease) (table 2.2).  Caspase 3 activation was increased in HeLa and HT29 cells 
when combination treatment was applied (figure 2.4).  This could indicate that the 
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decreased IC50 values may be due to increased apoptosis.  The trypan blue assay 
show strong evidence that mangiferin favours apoptotic cell death instead of necrosis 
when applied in combination with oxaliplatin.  No significant differences were seen 
between the amount of LDH released with and without the addition of mangiferin to 
oxaliplatin (figure 2.2).  The DNA cell cycle analysis revealed that oxaliplatin causes 
an S-phase delay in the DNA cycle and that a combination with mangiferin caused an 
earlier, enhanced delay in this phase (figure 2.3).  It was previously found that 
oxaliplatin causes an S-phase delay in HT29 cells (Rakitina et al. 2007).  There was 
also an increase in the amount of cells in the sub-G1 (apoptotic) phase.  The DNA 
fragmentation assay revealed that more DNA fragmentation occurred when 
oxaliplatin was applied in combination with mangiferin (figure 2.5), but no significant 
difference was seen in the mitochondrial membrane potential (figure 2.6).  Table 2.4 
shows that resistance to oxaliplatin was counteracted by the combination with 
mangiferin in HeLa and HT29 cells, but not in MCF7 cells and the NFκB assay 
indicates that this may be due to a decrease in the activated NFκB levels when 
oxaliplatin is applied in combination with mangiferin (figure 2.7).  These results show 
great promise in improving the efficacy of oxaliplatin by combination treatment with 
mangiferin. It has previously been shown that reversal of oxaliplatin chemo-resistance 
can be achieved by NF-kB inhibition (Almendro et al. 2006) and that downregulation 
of NF-κB transactivation by pharmacological inhibitors enhances oxaliplatin 
cytotoxicity in several colon adenocarcinoma cell lines (Lagunas and Melendez-
Zajgla, 2008). 
 
CPA7 (Pt(NH3)2Cl3(NO2)) showed a decrease in the IC50 for all cell lines when 
applied in combination with mangiferin (table 2.2).  A slight increase in the 
percentage of activated caspase 3 occurred in the HeLa cells, but a decrease occurred 
in the HT29 cells; suggesting an alternative mode of action (parapoptosis) or a faster 
action in this cell line (figure 2.4).  The trypan blue assay showed that a decrease in 
the percentage of non-viable cells occurred in the HeLa cell line when CPA7 was 
applied in combination with mangiferin, but slight increases occurred in the HT29 and 
MCF7 cells (table 2.3), which may also be accounted for by an faster action of this 
drug.  There were no significant differences in the percentage LDH released in the 
HeLa cell line, but the HT29 and MCF7 cells showed a significant decrease in the 
amount of LDH released when applied in combination with mangiferin (figure 2.2).  
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When CPA7 was applied in combination with mangiferin, a later, enhanced S-phase 
delay occurred (as opposed to the earlier delay seen in the oxaliplatin combination 
treatment) (figure 2.3).  There was a decreased amount of DNA fragmentation when 
combined with mangiferin (figure 2.5), but an increase in the amount of depolarized 
cells (figure 2.6), indicating that apoptosis is occurring.  Table 2.4 indicated that the 
IC50 values decreased when applied in combination with mangiferin in all cell lines, 
but resistance was only counteracted in the MCF7 cell line.    The activated NFκB 
levels were increased in CPA7 resistant HT29 cells, but the addition of mangiferin 
decreased this amount (figure 2.7).  Not much has been published on CPA7 in the 
scientific literature before.  The biological effects of CPA7 were shown to include 
growth inhibition and apoptosis of malignant cells that harbour constitutively active 
Stat3.  These effects were found to be stronger and more selective against malignant 
cells that contain persistently active Stat3 than those that do not.  CPA7 is a platinum 
(IV) complex, in contrast to oxaliplatin, which is a platinum (II) complex (Turkson et 
al. 2004). 
 
Yol25 (Pt(hme)Cl2) showed lower IC50 values and thus better in vitro efficacy than 
cisplatin and oxaliplatin in all cell lines except in HT29 cells.  There was also a slight 
increase in the IC50 for the MCF7 cell line as compared to oxaliplatin (table 2.2).  
Therefore Yol 25 had a reduced anticancer action on HT29 cells compared to cisplatin 
and oxaliplatin.  Similarly it exhibited a higher IC50, when compared to CPA7, in 
HT29 cells.  In contrast to this, Yol 25 showed the most activated caspase 3 of all 
complexes tested (figure 2.4), indicating that apoptosis is occurring in the cells.  It 
also showed a slight decrease in LDH release in HT29 cells (figure 2.2).  This 
indicates decreased necrosis which will lead to less inflammation.  It caused an early 
S-phase delay in the DNA cell cycle when applied alone, as did CPA7, but not to such 
a great extent as CPA7.  No effect was seen on the subG1 phase (figure 2.3).  Less 
DNA fragmentation and mitochondrial membrane depolarization (figures 2.5 and 2.6) 
occurred when Yol 25 was applied alone as compared to oxaliplatin and CPA7.  This 
complex did not seem to induce resistance in HeLa and MCF7 cells, but did in HT29 
cells (table 2.4), which was probably caused by an increased activation of NFκB 
(figure 2.7).   
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In combination with mangiferin, Yol 25 showed a decrease in the IC50s (table 2.2).  
The activated caspase 3 levels decreased in both HeLa and HT29 cells when a 
combination treatment was applied (figure 2.4). This corresponds to the results 
obtained for CPA7 in the HT29 cell line.  This compound alone caused the most 
activation of caspase 3 of all the compounds tested.  This suggests that Yol 25 alone 
induces apoptosis via a caspase 3 activation pathway, but when applied in 
combination with mangiferin, this pathway does not play such a significant role any 
more and an alternate path is used.  This alternate path may very well be parapoptosis, 
as discussed above.  The trypan blue assay showed a decrease in the amount of non-
viable cells when applied in combination with mangiferin (table 2.3) and a significant 
increase in the LDH levels was seen in the HeLa cells, whereas a significant decrease 
occurred in the MCF7 cell line.  No effect was seen in the HT29 cell line (figure 2.2).  
The increase in the LDH levels seen in the HeLa cells might suggest that a certain 
amount of necrosis takes place when a combination is applied.  The DNA cell cycle 
results corresponds with those obtained for oxaliplatin in combination with 
mangiferin, since an earlier, enhanced delay in the S-phase was seen (figure 2.2).  
There was an increased amount of DNA fragmentation (figure 2.5) and an increased 
amount of depolarized cells (figure 2.6).  However, Yol 25 alone did not have a 
significantly higher amount of depolarized cells than the control cells; suggesting that 
Yol 25 does not rely on a mitochondrial induced apoptotic pathway when applied 
alone, again suggesting parapoptosis.  A decrease in the IC50 value was seen in the 
HT29 cells when combination treatment was applied.  It was also interesting to note 
that the HeLa and MCF7 cell lines did not seem to become resistant to this compound 
whether it was applied alone or in combination (table 2.4).  Interestingly, there was an 
increase in the amount of activated NFκB when applied in combination; however, 
after an additional 48 hour treatment with Yol 25 alone, this value decreased for the 
cells rendered resistant in the presence of mangiferin whereas those rendered resistant 
in the absence of mangiferin did not seem to affect the NFκB levels (figure 2.7). 
 
In conclusion it seems that Yol 25 might be a worthy novel anticancer drug, even 
though the IC50s were higher than that of the positive controls.  This, unfortunately, 
will necessitate the administration of a higher dose of this drug, which might cause 
more severe toxic side effects.  However, the application of this drug in combination 
with mangiferin might be the answer to this, since this combination lowered the IC50s 
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significantly and might cause parapoptosis to occur.  Further testing of this drug, 
alone and in combination with mangiferin is therefore recommended.      
 
Yol 29.1 (Pt(ama)Cl2) showed decreased IC50s in HeLa cells, compared to cisplatin 
and oxaliplatin, and in MCF7 cells, compared to oxaliplatin and CPA7.  In HT29 cells 
it had a slightly lower IC50 than oxaliplatin, cisplatin and CPA7.  This drug alone is 
more effective in terms of IC50 than Yol 25 alone (table 2.2).  Yol 29.1 also induced 
more caspase 3 than either oxaliplatin or CPA7 (figure 2.4).  No effect on LDH 
release was seen in HeLa and HT29 cells, but a significant decrease was observed in 
the MCF7 cell line (figure 2.2).  Its effect on the DNA cell cycle was similar to that of 
CPA7 and Yol 25, causing an early S phase delay.  There were slightly more cells in 
the subG1 phase than for Yol 25 (figure 2.3).  Yol 29.1 caused more DNA 
fragmentation than oxaliplatin, but less than CPA7 (figure 2.5) and exhibited the most 
depolarization of the mitochondrial membrane of all treatments, including the positive 
controls (figure 2.6).  This suggests that a mitochondrial induced apoptotic pathway is 
activated by this drug.  Yol 29.1 caused resistance in HeLa and HT29 cells, but not in 
MCF7 cells (table 2.4).  The resistance in HeLa and HT29 was most probably as a 
result of the much higher levels of activated NFκB (figure 2.7).   
 
When Yol 29.1 was applied in combination with mangiferin it showed a decrease in 
the IC50s (table 2.2) as well as decreases in the amount of activated caspase 3, similar 
to Yol 25 (figure 2.4).  A decrease in the amount of trypan blue positive (non-viable) 
cells was seen in the HeLa cell line, but in both the HT29 and MCF7 cell lines an 
increase occurred (table 2.3).  There was a significant decrease in the amount of LDH 
release in the MCF7 cells, but no effect was seen in the HeLa and HT29 cell lines 
(figure 2.2).  Yol 29.1 in combination with mangiferin acts similar to CPA7 on the 
DNA cell cycle and a later, enhanced S-phase delay was seen.  However this delay 
could be interpreted as a late S/ early G2/M phase delay as opposed to a strict S-phase 
delay as observed for CPA7 (figure 2.3).  An increase in the amount of DNA 
fragmentation (figure 2.5) and the amount of depolarized cells (figure 2.6) was 
observed for combination treatments, but the addition of mangiferin caused increased 
IC50s in the cell lines.  It also seems that resistance was not induced in the MCF7 cell 
line (table 2.4).  The resistance-induced HT29 cells showed a decreased level of 
activated NFκB when applied in combination with mangiferin (figure 2.7).   
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In conclusion, Yol 29.1 seems to be more efficient that Yol 25 in terms of IC50 
values, but causes resistance in both HeLa and HT29 cells.  Furthermore, the addition 
of mangiferin does not decrease the IC50 values, but rather increases it.  However, 
NFκB levels decrease in the presence of mangiferin, suggesting that NFκB does not 
play a role in resistance induction by this compound.  Yol 29.1 alone would be more 
efficient than Yol 25, but the mechanism of resistance should be studied and other 
combination therapies investigated. 
  
Mar 4.1.4 (Pt(dach)(C2O4)NO2)Cl) shows lower IC50 values than cisplatin, 
oxaliplatin and CPA7, proving to be more efficient than any of the positive controls in 
terms of IC50s (table 2.2).  It also showed increased caspase 3 levels compared to the 
positive controls (figure 2.4).  However, much higher LDH levels were obtained than 
for the positive controls in the HeLa cell line, with lower levels obtained in HT29 and 
MCF7 cells compared to CPA7, but not to oxaliplatin (figure 2.2).  Mar 4.1.4 acted 
similar to oxaliplatin by causing a late S-phase delay in the DNA cell cycle as well as 
resulting in a similar amount of cells in the subG1 phase (figure 2.3).  An increased 
amount of DNA fragmentation was seen compared to oxaliplatin, but not to CPA7 
(figure 2.5) and more depolarization of the mitochondrial membrane occurred 
compared to the positive controls (figure 2.6).  This drug did not induce resistance in 
HeLa and MCF7 cells, but did in HT29 cells (table 2.4).  Interestingly, the amount of 
activated NFκB in the HT29 cell line decreased, suggesting that NFκB does not play a 
significant role in the induction of resistance by this drug (figure 2.7).   
 
In combination with mangiferin a decrease in the IC50 values was observed, 
especially for the MCF7 cell line (3.1 fold decrease as opposed to a 3.4 fold decrease 
for oxaliplatin) (table 2.2).  Combination treatment did not affect the caspase 3 levels 
in the HeLa cell line, but a decrease in the level of activated caspase 3 was seen in the 
HT29 cell line.  This again suggests that an alternate apoptotic path is activated (as for 
CPA7, Yol 25 and Yol 29.1) (figure 2.4).  Using the trypan blue assay, a decrease in 
the amount of non-viable cells was found in the HeLa and HT29 cells, but not in the 
MCF7 cells (table 2.3).  No significant differences in the LDH levels were observed 
(figure 2.2) but similarly to Yol 29.1 it caused a later, enhanced delay in the late S/ 
early G2/M phase of the DNA cycle (figure 2.3).  There was an increase in the 
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amount of DNA fragmentation when applied in combination with mangiferin (figure 
2.5), but no effect on the mitochondrial membrane potential was seen (figure 2.6).  
This was also true for oxaliplatin.  This compound did not induce resistance in the 
HeLa and MCF7 cell lines and the presence of mangiferin did not affect the IC50s of 
the resistance-induced cells, but it did lower the IC50s for the normal cells.  
Resistance was induced in the HT29 cell line but a decrease in the NFκB levels was 
seen in resistant cells, contradicting the belief that resistance can be linked to 
increased NFκB levels.  When resistance was induced in the presence of mangiferin, 
the level of NFκB increased to above that of the control cells, as was expected (figure 
2.7). 
 
In conclusion, Mar 4.1.4 seems to be the most effective drug tested in this study, 
including the positive controls.  The addition of mangiferin further lowers the IC50 
values of this drug, rendering it even more effective.  The fact that no resistance was 
induced in HeLa and MCF7 cells shows even more promise for this drug.  
Unfortunately the addition of mangiferin does not seem to counteract the resistance 
induced in the HT29 cells, and further studies into the mechanisms applied to induce 
resistance is required.  Mar 4.1.4 is a “pro-drug” for oxaliplatin and is reduced, 
amongst others, to oxaliplatin in the body.  This might explain why it acts similar to 
oxaliplatin in some of these experiments.  The slower breakdown of this drug will 
probably enhance its efficacy and eliminate/ reduce some of the toxic side-effects.  In 
light of the increased efficacy and apoptosis that occurs in combination with 
mangiferin, further investigation into such a combination treatment is strongly 
recommended.     
 
In this study the combined mechanism of the anticancer action of platinum containing 
complexes in combination with mangiferin was investigated.  The present study 
indicates that mangiferin in combination with platinum anticancer drugs favours 
apoptotic cell death and thereby improves their efficacy in vitro.  In addition, 
combination therapy with mangiferin may also counteract the development of 
resistance in cancer cell lines. 
 
Unfortunately no published literature could be found to indicate how much 
mangiferin is present in a cup of tea such as Honeybush, nor how much mangiferin is 
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absorbed through the gastro-intestinal tract.  Such information would assist in 
extrapolating our in vitro results to the in vivo situation.  However, the most 
significant decrease in the IC50 values was seen in colon cancer cells treated with 
oxaliplatin in combination with mangiferin.  In this instance, where the tea would be 
taken orally and the epithelial cells of the gastro-intestinal tract would be directly 
exposed to the mangiferin, the absorption of the tea is not that relevant, which renders 
these results even more promising.  
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CHAPTER 3 
FINAL PERSPECTIVE ON THE PRESENT STUDY 
 
This work was initiated in an effort to identify novel platinum compounds with 
improved anticancer activity, as stated in the introduction.  It is however very difficult 
to determine what a good anticancer agent is.  For example, is cisplatin a good 
anticancer agent?  Although it has a high “killing rate”, it also has numerous toxic 
side effects.  Its tendency to induce resistance in cells is again a negative effect.  Yet, 
in spite of this, for the last approximately thirty years it has been rather commonly 
used. 
 
Is oxaliplatin a good agent?  It has a much lower “killing rate” than cisplatin, however 
it has lesser side effects and does not render certain cancer cells resistant.  It is 
presently rated number one for the treatment of colon cancer. 
 
The above-illustrated complexities should however not discourage the search for new 
improved anticancer agents, especially if the severity of the disease is taken into 
account.  It is realized that the monitoring of the anticancer action of the compounds 
in this work can only be considered as first order to select those compounds that 
exhibited potential.  Even those that are in the latter category should be tested further 
in biological systems. 
 
A significant number of compounds have been tested, and as expected, a much 
smaller number proved to have potential according to the experiments performed in 
this study.  A few compounds were shown to be worthy of follow-up tests, namely 
Yol 25 (Pt(hme)Cl2), Yol 29.1 (Pt(ama)Cl2)  and Mar 4.1.4 (Pt(dach)(C2O4)NO2)Cl).  
Furthermore, some of these complexes can be regarded as very promising for cancer 
treatment, since it does not induce resistance in some cancer cell lines.  It was also 
found that the addition of mangiferin can improve the efficacy of these platinum 
drugs as well as reduce the degree of resistance induced by these complexes.  This 
highlights the importance of investigating novel combination treatments with 
platinum drugs, in order to improve its efficacy, lessen toxic side effects as well as 
reduce resistance. 
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It would be interesting to identify the exact nature of cell cycle arrest by investigating 
the presence of specific cyclins and cyclin-dependent kinases.  Another interesting 
aspect would be to investigate the effect that these compounds, alone and in 
combination with mangiferin, have on STAT3 activation, p53 status, and/or Bcl/ Bax 
family expression activation.  There is thought to be a positive link between the 
simultaneous deactivation of STAT3 and NFκB during targeting cancer cells.  These 
above-mentioned experiments can be performed using flow cytometry.   
 
There is also a possibility that the toxicity of these drugs can be less than that of the 
drugs currently used to treat cancer.  In addition, the combination of these drugs with 
mangiferin may further decrease these toxic side-effects.  Therefore, the toxicity of 
these drugs (particularly nephrotoxicity and neurotoxicity), on the internal organs, 
alone and as a combination therapy, should be investigated.  This could be performed 
by using, for example, Chang liver (non-malignant) and HepG2 (cancerous) cells to 
perform dose response curves.  This will indicate whether these compounds are cyto-
specific or toxic to normal liver cells.    
 
A neuronal cell line, such as the neuron-like rat pheochromocytoma cell line, PC-12, 
can be used to determine the effect of these compounds, alone as well as in 
combination with mangiferin, on the neurons.  After treatment the cells can be fixed 
and permeabilized before being stained with a fluorescent dye, and the neuron lengths 
can be observed microscopically.  This may also aid in determining whether 
mangiferin could rescue the neurites from the damage induced by the compounds.  
However, since certain limitations exist for in vitro studies, ultimately these 
experiments would have to be performed in vivo, before proceeding to clinical trials. 
 
The work created some new concepts, which will be worthwhile pursuing for the 
further search of improved anticancer agents.  Based on the results obtained in this 
study it can be concluded that mangiferin might be used as a combination therapy 
with platinum anticancer drugs in order to increase the efficacy of these drugs as well 
as counteract the development of drug-resistant cells.   
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